WO2025033358A1 - 免疫細胞の製造方法 - Google Patents
免疫細胞の製造方法 Download PDFInfo
- Publication number
- WO2025033358A1 WO2025033358A1 PCT/JP2024/027781 JP2024027781W WO2025033358A1 WO 2025033358 A1 WO2025033358 A1 WO 2025033358A1 JP 2024027781 W JP2024027781 W JP 2024027781W WO 2025033358 A1 WO2025033358 A1 WO 2025033358A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- car
- expressing
- caar
- progenitor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to a method for producing immune cells that express exogenous receptors, such as T cell receptors (TCR) and chimeric antigen receptors (CAR), that specifically recognize a desired antigen, a method for producing an immune cell therapy using said method, a method for treating diseases using said immune cells, and a method for mass-producing T/NK precursor cells.
- exogenous receptors such as T cell receptors (TCR) and chimeric antigen receptors (CAR)
- TCR T cell receptors
- CAR chimeric antigen receptors
- T cells TCR-T cells, CAR-T cells
- CAR-T cells tumor-specific TCR or chimeric antigen receptor (CAR)
- CAR-NK cells NK cells
- Methods for producing TCR-T cells, CAR-T cells and CAR-NK cells for use in immune cell therapy include producing them by introducing TCR genes or CAR genes into T cells/NK cells collected from the patient himself, T cells/NK cells derived from umbilical cord blood, etc., and known T cell lines/NK cell lines, as well as a method for preparing CAR-NK cells by introducing CAR genes into iPS cells and inducing their differentiation into NK cells (Non-Patent Document 1).
- CAR-T cells are produced from leukocytes collected from the patient himself by leukocyte apheresis.
- TCR-T cells and CAR-T/CAR-NK cells become exhausted within the patient's body, and are unable to maintain sufficient cytotoxic activity. From the perspective of sustaining the therapeutic effect by appropriately repeating cell transplants, it is essential to develop a method for stably producing these tumor-specific immune cells, but such development is insufficient.
- Non-Patent Documents 2 and 3 and Patent Document 1 which can amplify large quantities of mouse and human pluripotent blood progenitor cells.
- Id3 is introduced into hematopoietic stem and progenitor cells (HSPCs) to inhibit intracellular E2A, and the cells are then cultured under conditions that induce differentiation into B cells.
- HSPCs hematopoietic stem and progenitor cells
- iLS induced leukocyte stem
- the inventors of the present application have also reported a method for generating and amplifying T/NK precursor cells (pT/NK cells) capable of differentiating into T cells and NK cells in a study using mice (Non-Patent Documents 2, 4, 5).
- IL-7, SCF, and Flt3-L are each added to the culture medium at 10 ng/mL, and mouse hematopoietic stem/progenitor cells are cultured in the presence of Notch ligands.
- This generates pT/NK cells that maintain pluripotency (the ability to differentiate into T cells, NK cells, and myeloid cells) and have the ability to self-replicate. It has been confirmed that this method also makes it possible to amplify mouse pT/NK cells ex vivo for at least several months.
- a method developed by another group is, for example, a method of expanding and culturing mouse hematopoietic stem cells in an undifferentiated state by culturing hematopoietic stem cells in a medium containing polyvinyl alcohol instead of serum albumin (Non-Patent Document 6). This method also makes it possible to expand and culture mouse hematopoietic stem cells in an undifferentiated state for more than one month.
- One object of the present invention is to provide a means for stably producing TCR-T cells and CAR-T/CAR-NK cells.
- a further object of the present invention is to provide a means for treating diseases by applying said means.
- Another object of the present invention is that in tests in which the methods described in Non-Patent Documents 2, 4, and 5 using mice were applied to human hematopoietic stem cells, it was newly confirmed that there is a limit to the expansion of human T/NK precursor cells. Therefore, the object of the present invention also includes the development of a new method that improves the expansion efficiency of human T/NK precursor cells for application to human immune cell therapy.
- TCR- or CAR-expressing immune cells can be prepared efficiently and stably by introducing a TCR gene or a CAR gene into pluripotent blood progenitor cells such as artificial white blood stem cells or T/NK progenitor cells, amplifying them, and inducing their differentiation into immune cells such as T cells, NK cells, and macrophages; that TCR- or CAR-expressing immune cells can be mass-produced by preparing these pluripotent blood progenitor cells using the method for amplifying artificial white blood stem cells or T/NK progenitor cells developed by the inventors' group; and that TCR- or CAR-expressing immune cells can also be prepared efficiently and stably when the pluripotent blood progenitor cells prepared by this amplification method are differentiated into immune cells and then the TCR or CAR gene is introduced.
- pluripotent blood progenitor cells such as artificial white blood stem cells or T/NK progenitor cells, amplifying them, and inducing their differentiation into immune cells such as T cells,
- the inventors discovered that by reducing the concentrations of SCF, Flt3-L, and IL-7 to less than 10 ng/mL in the process of preparing human T/NK precursor cells, the expansion efficiency of human pT/NK cells is significantly increased, and further that under culture conditions in which TPO or M-CSF is combined, a 300- to 600-fold expansion is achieved, and that human CAR-NK cells prepared from human T/NK precursor cells produced under these culture conditions have good anti-tumor effects.
- the inventors have completed the present invention, which encompasses the following aspects:
- a method for producing immune cells expressing an exogenous receptor which is a T cell receptor (TCR), a chimeric antigen receptor (CAR), or a chimeric autoantibody receptor (CAAR), comprising: preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells; A method comprising: preparing multipotent blood progenitor cells that express the exogenous receptor by introducing a gene encoding the exogenous receptor into the multipotent blood progenitor cells; and inducing differentiation of the multipotent blood progenitor cells that express the exogenous receptor into immune cells.
- TCR T cell receptor
- CAR chimeric antigen receptor
- CAAR chimeric autoantibody receptor
- a method for producing immune cells expressing an exogenous receptor that is a TCR, a CAR, or a CAAR comprising: preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells; A method comprising the steps of: inducing differentiation of multipotent blood progenitor cells into immune cells; and introducing a gene encoding the exogenous receptor into immune cells, wherein the multipotent blood progenitor cells are induced leukocyte stem cells or T/NK progenitor cells.
- the multipotent blood progenitor cells are artificial leukocyte stem cells or T/NK progenitor cells.
- the multipotent blood progenitor cells are artificial white blood stem cells
- the artificial white blood stem cells are prepared by culturing a cell population containing hematopoietic stem cells under conditions that induce differentiation into B cells while inhibiting the function of the intracellular transcription factor E2A.
- E2A the function of E2A is inhibited by forcibly expressing the differentiation inhibitor Id in hematopoietic stem cells.
- the multipotent blood progenitor cells are T/NK progenitor cells
- the T/NK progenitor cells are prepared by culturing a cell population containing hematopoietic stem cells in the presence of a Notch ligand.
- a cell population containing hematopoietic stem cells is cultured in a medium containing SCF, TPO and G-CSF at concentrations of 100 ng/mL or more each in the absence of a Notch ligand, and then cultured in the presence of a Notch ligand.
- a method for producing an immune cell therapy agent for a disease treatable by immune cell therapy comprising: preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells; A step of preparing multipotent blood progenitor cells expressing an exogenous receptor, which is a TCR or CAR that specifically recognizes a CAAR or a target antigen (e.g., a tumor antigen), by introducing a gene encoding the exogenous receptor into the multipotent blood progenitor cells; A step of inducing differentiation of multipotent blood progenitor cells expressing the exogenous receptor into T cells, thereby preparing T cells expressing the exogenous receptor (TCR-T, CAR-T or CAAR-T cells); A method comprising the steps of: TCR-stimulating TCR-T, CAR-T or CAAR-T cells and inducing their differentiation into CD8-positive cytotoxic TCR-
- a method for producing an immune cell therapy agent for a disease treatable by immune cell therapy comprising: preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells; A step of inducing differentiation of multipotent blood progenitor cells into T cells; The method includes the steps of: preparing CD8-positive cytotoxic TCR-T, CAR-T or CAAR-T cells by introducing a gene encoding an exogenous receptor that is a TCR or CAR that specifically recognizes a CAAR or a target antigen (e.g., a tumor antigen) after TCR stimulation of the T cells; and preparing the CD8-positive cytotoxic TCR-T or CAR-T cells as an immune cell therapy for a disease caused by cells expressing the antigen (e.g., a tumor expressing a tumor antigen), or preparing the CD8-positive cytotoxic CAAR-T cells as an immune cell therapy for a disease caused by cells expressing the antigen (e.g.,
- a method for producing an immune cell therapy agent for a disease treatable by immune cell therapy comprising: preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells; A step of preparing multipotent blood progenitor cells expressing a chimeric receptor, which is a CAAR or a CAR that specifically recognizes a tumor antigen, by introducing a gene encoding the chimeric receptor into the multipotent blood progenitor cells; A method comprising the steps of: preparing NK cells (CAR-NK or CAAR-NK cells) or macrophages (CAR-macrophages or CAAR-macrophages) expressing the chimeric receptor by inducing differentiation of multipotent blood progenitor cells expressing the chimeric receptor into NK cells or macrophages; and preparing the CAR-NK cells or CAR-macrophages as an immune cell therapy for a disease caused by cells expressing
- a disease treatable by immune cell therapy e.g.,
- a method for producing an immune cell therapy agent for a disease treatable by immune cell therapy comprising: preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells; A step of inducing differentiation of multipotent blood progenitor cells into NK cells or macrophages; A method comprising the steps of: preparing NK cells (CAR-NK or CAAR-NK cells) or macrophages (CAR-macrophages or CAAR-macrophages) expressing a chimeric receptor by introducing a gene encoding a chimeric receptor that is a CAAR or a CAR that specifically recognizes a target antigen (e.g., a tumor antigen) after receptor stimulation of NK cells or macrophages; and preparing the CAR-NK cells or CAR-macrophages as an immune cell therapy for a disease caused by cells expressing the antigen (e.g., a tumor expressing
- a method of treating a disease treatable by immune cell therapy comprising: preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells; A step of preparing multipotent blood progenitor cells expressing an exogenous receptor, which is a TCR or CAR that specifically recognizes a CAAR or a target antigen (e.g., a tumor antigen), by introducing a gene encoding the exogenous receptor into the multipotent blood progenitor cells; A step of inducing differentiation of multipotent blood progenitor cells expressing the exogenous receptor into T cells, thereby preparing TCR-T, CAR-T or CAAR-T cells, which are T cells expressing the exogenous receptor; A method comprising the steps of: TCR-stimulating TCR-T, CAR-T or CAAR-T cells and inducing their differentiation into CD8-positive cytotoxic TCR
- a method of treating a disease treatable by immune cell therapy comprising: preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells; A step of inducing differentiation of multipotent blood progenitor cells into T cells; The method includes the steps of: preparing CD8-positive cytotoxic TCR-T, CAR-T or CAAR-T cells by introducing a gene encoding an exogenous receptor that is a TCR or CAR that specifically recognizes a CAAR or a target antigen (e.g., a tumor antigen) after TCR stimulation of the T cells; and administering the CD8-positive cytotoxic TCR-T or CAR-T cells to a patient having a disease caused by cells expressing the antigen (e.g., a tumor expressing a tumor antigen), or administering the CD8-positive cytotoxic CAAR-T cells to a patient with an autoimmune
- a method of treating a disease treatable by immune cell therapy comprising: preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells; A step of preparing multipotent blood progenitor cells expressing a chimeric receptor, which is a CAAR or a CAR that specifically recognizes a target antigen (e.g., a tumor antigen), by introducing a gene encoding the chimeric receptor into the multipotent blood progenitor cells; A step of preparing chimeric receptor-expressing immune cells, which are CAR-NK cells, CAAR-NK cells, CAR-macrophages, or CAAR-macrophages, by inducing differentiation of the multipotent blood progenitor cells expressing the chimeric receptor into NK cells or macrophages; A method comprising administering CAR-NK cells or CAR-macrophages to a patient having a disease caused by
- a method of treating a disease treatable by immune cell therapy comprising: preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells; A step of inducing differentiation of multipotent blood progenitor cells into NK cells or macrophages; A method comprising the steps of: preparing CAR-NK cells, CAAR-NK, CAR-macrophages or CAAR-macrophages by introducing a gene encoding a chimeric receptor that is a CAAR or a CAR that specifically recognizes a target antigen (e.g., a tumor antigen) after receptor stimulation of NK cells or macrophages; and administering the CAR-NK cells or CAR-
- a disease treatable by immune cell therapy e.g., a tumor or an autoimmune disease
- a method for treating a disease comprising: A step of preparing a CAR-macrophage by the following (1) or (2): (1) preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells, introducing a gene encoding a CAR that specifically recognizes a target antigen (e.g., a tumor antigen) into the multipotent blood progenitor cells to prepare multipotent blood progenitor cells expressing the CAR, and then inducing the differentiation of the CAR-expressing multipotent blood progenitor cells into macrophages; (2) preparing artificial leukocyte stem cells or T/NK precursor cells from a cell population containing hematopoietic stem cells, inducing their differentiation into macrophages, stimulating the receptor, and then introducing a gene encoding the CAR; A step of preparing CAR-T cells by the following (3) or
- a method for treating a disease comprising: A step of preparing CAR-macrophages by the following step (1) or (2): (1) preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells, introducing a gene encoding a CAR that specifically recognizes a target antigen (e.g., a tumor antigen) into the multipotent blood progenitor cells to prepare multipotent blood progenitor cells expressing the CAR, and then inducing the differentiation of the CAR-expressing multipotent blood progenitor cells into macrophages; (2) preparing artificial leukocyte stem cells or T/NK precursor cells from a cell population containing hematopoietic stem cells, inducing their differentiation into macrophages, stimulating the receptor, and then introducing a gene encoding the CAR; A step of preparing CAR-NK cells by the following step (5) or
- step (5) further comprises inducing differentiation of the CAR-expressing multipotent blood progenitor cells into NK cells to prepare CAR-NK cells, and then receptor-stimulating the CAR-NK cells.
- step (1) further comprises inducing differentiation of the CAR-expressing multipotent blood progenitor cells into macrophages to prepare CAR-macrophages, and then receptor-stimulating the CAR-macrophages.
- the target antigen is a tumor antigen
- the disease caused by cells expressing the antigen is a tumor expressing the tumor antigen
- the present invention further provides the following methods, cells, etc.
- a method for producing human T/NK progenitor cells comprising the step of culturing a cell population containing human hematopoietic stem cells in a medium containing SCF, Flt3-L, and IL-7, each at a concentration of 1 ng/mL or more and less than 10 ng/mL, in the presence of a Notch ligand.
- the medium further contains at least one of TPO and M-CSF.
- the cell population containing human hematopoietic stem cells is a cell population obtained by culturing a cell population containing human hematopoietic stem cells in a medium containing SCF, TPO, and G-CSF at concentrations of 100 ng/mL or more, respectively, in the absence of a Notch ligand.
- a method for producing human NK cells comprising: producing human T/NK precursor cells by the method according to any one of [26] to [28]; and inducing differentiation of the produced human T/NK precursor cells into human NK cells by culturing the produced human T/NK precursor cells in a medium containing IL-7, Flt3-L, SCF and IL-15 in the absence of a Notch ligand.
- a cultured human T/NK progenitor cell that is CD122-positive wherein the cultured human T/NK progenitor cell is preferably a cell that further satisfies the condition of expressing one, two, three, four, five, or six surface antigens selected from the group consisting of CD3-negative, CD4-negative, CD8-negative, CD56-negative, CD161-negative, and CD7-positive.
- Cultured human NK cells which are characterized by having lower expression of CD16 and KIR, indicators of maturity, and lower expression of the exhaustion marker TIGIT, than human cord blood NK cells isolated from human umbilical cord blood, and therefore are more immature and less exhausted than the human cord blood NK cells.
- the above-mentioned method for producing an immune cell therapy agent for a disease treatable by immune cell therapy of the present invention includes the following aspects.
- [i-1] A method for producing an immune cell therapy agent described in any one of [12] to [16], wherein the multipotent blood progenitor cells are human T/NK progenitor cells, and in the step of preparing the multipotent blood progenitor cells, human T/NK progenitor cells are produced from a cell population containing human hematopoietic stem cells by the method described in any one of [26] to [28].
- [i-2] A method for producing an immune cell therapy agent described in any one of [14] to [16], wherein the multipotent blood progenitor cells are human T/NK progenitor cells and the immune cells are human NK cells, and in the step of preparing the multipotent blood progenitor cells, human T/NK progenitor cells are produced from a cell population containing human hematopoietic stem cells by the method described in any one of [26] to [28], and in the step of inducing the differentiation of the multipotent blood progenitor cells into immune cells, the human T/NK progenitor cells are cultured in a medium containing IL-7, Flt3-L, SCF and IL-15 in the absence of a Notch ligand, thereby inducing the differentiation of human NK cells.
- the above-mentioned method of the present invention for treating a disease treatable by immune cell therapy in a patient includes the following aspects.
- [ii-1] A method for treating a disease treatable by immune cell therapy in a patient according to any one of [17] to [21], wherein the multipotent blood progenitor cells are human T/NK progenitor cells, and in the step of preparing the multipotent blood progenitor cells, human T/NK progenitor cells are produced from a cell population containing human hematopoietic stem cells by the method according to any one of [26] to [28].
- [ii-2] A method for treating a disease in a patient described in any one of [19] to [21], wherein the multipotent blood progenitor cells are human T/NK progenitor cells and the immune cells are human NK cells, and in the step of preparing the multipotent blood progenitor cells, human T/NK progenitor cells are produced from a cell population containing human hematopoietic stem cells by the method described in any one of [26] to [28], and in the step of inducing the differentiation of the multipotent blood progenitor cells into immune cells, the human T/NK progenitor cells are cultured in a medium containing IL-7, Flt-3L, SCF and IL-15 in the absence of a Notch ligand, thereby inducing the differentiation of human NK cells.
- the multipotent blood progenitor cells are human T/NK progenitor cells and the immune cells are human NK cells.
- the above-mentioned method of the present invention for treating a disease caused by cells expressing a target antigen in a patient includes the following aspects.
- [iii-1] A method for treating a disease caused by cells expressing a target antigen of a patient described in any one of [22] to [25], wherein the multipotent blood progenitor cells are human T/NK progenitor cells, and the preparation of the multipotent blood progenitor cells from a cell population containing hematopoietic stem cells is performed by the method described in any one of [26] to [28].
- [iii-2] A method for treating a disease caused by cells expressing a target antigen in a patient according to [23] or [24], wherein the multipotent blood progenitor cells are human T/NK progenitor cells, the NK cells are human NK cells, the preparation of the multipotent blood progenitor cells from a cell population containing hematopoietic stem cells is carried out by the method according to any one of [26] to [28], and the induction of differentiation into the NK cells is carried out by culturing the human T/NK progenitor cells in a medium containing IL-7, Flt3-L, SCF and IL-15 in the absence of a Notch ligand.
- the multipotent blood progenitor cells are human T/NK progenitor cells
- the NK cells are human NK cells
- the preparation of the multipotent blood progenitor cells from a cell population containing hematopoietic stem cells is carried out by the method according to any one of
- TCR/CAR/CAAR expressing immune cells such as TCR-T, CAR-T, CAAR-T, CAR-NK, and CAAR-NK cells.
- iLS cells are pluripotent blood progenitor cells with the ability to self-replicate and differentiate into leukocytes such as T cells and B cells.
- T/NK precursor cells pT/NK cells.
- CD34-positive hematopoietic stem cells are expanded by culturing hematopoietic stem and progenitor cells in the presence of high concentrations of cytokines. Next, by culturing the cells under Notch signal stimulation using OP9/delta-like-1 (DLL1) cells or similar, pT/NK cells with self-renewal ability that maintains pluripotency (the ability to differentiate into T cells, NK cells, and myeloid cells) are generated.
- DLL1 OP9/delta-like-1
- FIG. 1 Schematic diagram of the method for producing iLS cells expressing OTI TCR.
- FIG. 1 Schematic diagram of the method for producing iLS cells expressing OTI TCR.
- FIG. 1 FCM analysis of iLS cells transfected with the OTI TCR gene.
- OTI TCR-expressing iLS OTI TCR-expressing iLS (OTI TCR-iLS) cells with lineage marker (-), human CD25 (+) and GFP (+) were detected at a high frequency.
- FIG. 1 Schematic diagram of the process for inducing differentiation of T cells (CD4/CD8 double positive (DP) cells) from OTI TCR-iLS cells.
- DP double positive
- CD8+ T cells express the OTI TCR, and most of them are effector memory (EM) T cells and central memory (CM) T cells. During this process, the cells are expanded about 5-fold.
- EM effector memory
- CM central memory
- A Schematic process for the test to evaluate antigen-specific cytokine release from OTI TCR-iLS cell-derived CD8+ T cells (OTI T-iLS cells).
- B, C Results of intracellular staining of OTI TCR-iLS cell-derived CD8+ T cells stimulated with OVA antigen-presenting cells or PMA + ionomycin to examine cytokine release.
- B is a two-parameter histogram of FCM analysis
- C is a graph of this. Unstim.
- APC are cells co-cultured with mouse spleen cells not presenting OVA
- OVA + APC are cells stimulated with OVA antigen-presenting cells
- PMA/Iono are cells stimulated with PMA + ionomycin.
- MFI median fluorescence intensity.
- NT no treatment
- IL-2 IL-2 treatment only
- OTI-iLS + IL-2 treatment with OTI T-iLS cells and IL-2
- OTI-SP + IL-2 treatment with OTI Tg mouse spleen-derived T cells and IL-2.
- A Schematic of the process for inducing CAR-NK cells from iLS cells.
- B Schematic diagram of the mouse anti-CD19 CAR sequence of the retroviral vector used in the examples.
- C FCM analysis results of anti-CD19 CAR gene-introduced pT/NK cells (anti-CD19 CAR-pT/NK cells) and anti-CD19 CAR-introduced NK cells after differentiation induction (anti-CD19 CAR-NK cells), showing that a high percentage (over 70%) of anti-CD19 CAR-NK cells were generated.
- FCM analysis one week after the start of induction (Day 7) confirmed the generation of CD11b-positive, F4/80-positive, MHC class II (I-A)-positive macrophages.
- Top Schematic of the process for producing pT/NK cells from human umbilical cord blood CD34 positive cells (hCB-CD34 positive cells) and inducing their differentiation into NK cells.
- Bottom The expression of each surface antigen marker molecule was examined by FCM analysis on days 17 (left) and 25 (middle) from the start of culturing hCB-CD34 positive cells.
- pT/NK cells isolated using a cell sorter from the cell population on day 17 from the start of culturing and human umbilical cord blood hematopoietic stem/progenitor cells (hCB-HSPCs) obtained by expanding hCB-CD34 positive cells in Stemline II medium were each cultured under NK cell differentiation inducing conditions, and the numbers of NK cells generated were compared (right).
- NK cells derived from pT/NK cells were stimulated by co-culture with the target cells, the K562 leukemia cell line (K562 cells), or by treatment with PMA + ionomycin, and their cytokine release ability was analyzed by FCM.
- Cytotoxic activity of pT/NK cell-derived NK cells and hCB-HSPC-derived NK cells against K562 cells Schematic diagram of the human anti-CD19 CAR sequence and anti-GD2 CAR sequence of the lentiviral vector used to generate pT/NK cell-derived anti-CD19 CAR-NK cells and anti-GD2 CAR-NK cells (top).
- FCM analysis of the marker protein Venus confirmed that expression of the introduced gene was maintained (bottom).
- Mock Cells into which only Venus was introduced via lentivirus.
- pT/NK cells were transduced with a CAR gene-expressing lentivirus produced using a GALV envelope. FCM analysis of the marker protein Venus confirmed that expression of the transgene was maintained. Mock cells were transduced with only Venus via lentivirus. CAR-pT/NK cells were transduced with a CAR gene-expressing lentivirus produced using a GALV envelope, and induced to differentiate into NK cells, yielding pT/NK cell-derived NK cells that stably express the CAR gene. Mock cells were transduced with only Venus via lentivirus.
- Mouse bone marrow-derived hematopoietic stem/progenitor cells (Mouse HSPCs, Lineage-Sca1-ckit+: LSK) were cultured on OP9/DLL1 feeder cells in the medium containing SCF, IL-7 and Flt3-L at concentrations of 10 ng/ml or 30 ng/ml, respectively, for two weeks, after which the number of pT/NK cells was measured.
- SCF SCF
- IL-7 IL-7
- Flt3-L Flt3-L
- the top row shows an outline of the culture process.
- the bottom left row shows the number of pT/NK cells measured after 6 weeks of culture under cytokine concentrations 1 to 13 shown in Table 1.
- the bottom right row shows a graph showing the number of pT/NK cells obtained over time in culture under conditions 1 and 4.
- A Outline of the culture protocol in Example B-2.
- B Proliferation rate of cells from hCB-CD34 positive cells.
- C Results of FCM analysis after NK cell generation.
- D Number of NK cells produced when NK cells were directly induced from hCB-HSPCs and when pT/NK cell expansion method was used.
- Example B-3 cell proliferation rate after culturing NK cells collected from human umbilical cord blood (CB-NK cells), NK cells collected from human peripheral blood (PB-NK cells), and NK cells derived from human pT/NK cells in MEM ⁇ medium supplemented with 10 ng/ml rhIL-15 for two weeks.
- B Expansion rate when mitomycin-treated aAPC and each NK cell were mixed at an E:T ratio of 1:2 and the NK cells were expanded in MEM ⁇ medium containing 200 IU/ml rhIL-2.
- FIG. 1 shows the results of evaluating the expression levels of NK cell-associated receptors in pT/NK cell-derived NK cells by FCM analysis in Example B-4 (one-parameter histogram).
- FIG. 1 shows the results of evaluating the expression level of NK cell-associated receptors in pT/NK cell-derived NK cells by FCM analysis in Example B-4 (a graph of a one-parameter histogram). This is the result of comparing the cytotoxic activity of pT/NK cell-derived NK cells against K562 cells with PB-NK cells or CB-NK cells in Example B-5.
- NK cells and K562 cells were mixed at various E:T ratios and co-cultured for 4 hours, after which the proportion of dead K562 cells was analyzed by FCM.
- B, C Evaluation of the expression level of effector molecules produced by activated NK cells. B is a two-parameter histogram, and C is a graph of this. The results of evaluating the effect of cryopreservation of NK cells derived from human pT/NK cells in Example B-6.
- A Recovery rate of NK cells derived from pT/NK cells after freezing and thawing (cell number after freezing/cell number before freezing ⁇ 100).
- B Proliferation ability of NK cells derived from human pT/NK cells after freezing and thawing.
- Example B-7 Cytotoxic activity of NK cells derived from frozen and thawed pT/NK cells against K562 cells.
- Example B-7 factors that promote the differentiation and proliferation of hCB-HSPCs into pT/NK cells were explored.
- hCB-HSPCs were cultured on OP9/DLL1 feeder cells in the presence of 5 ng/ml each of rhIL-7, rhFlt3-L and rhSCF, and 10 ng/ml of each cytokine or 0.1 mM nicotinamide was added, and the expansion rate of pT/NK cells was calculated.
- Example B-8 Results of investigating the concentration at which TPO or M-CSF promotes the generation of human pT/NK cells.
- hCB-HSPCs were cultured on OP9/DLL1 feeder cells in the presence of rhIL-7, rhFlt3-L and rhSCF at 5 ng/ml each, to which TPO or M-CSF was added at concentrations of 0-50 ng/ml, and the number of pT/NK cells per HSPC was investigated.
- the results of evaluating the differentiation ability of human pT/NK cells expanded by adding TPO or M-CSF into NK cells in Example B-9.
- Example B-10 the results of investigating whether TPO is also effective in inducing pT/NK cells from human bone marrow-derived HSPCs (hBM-HSPCs).
- the top row shows an outline of the culture protocol.
- the middle row shows FCM analysis of pT/NK cells generated and expanded from hBM-HSPCs, and NK cells induced from these pT/NK cells.
- the bottom row shows the results of comparing the number of NK cells induced from pT/NK cells expanded for 5 weeks using this culture system with and without TPO.
- the expression levels of NK cell-associated receptors in pT/NK-derived NK cells induced from hBM-HSPCs were evaluated by FCM analysis (one-parameter histogram).
- NK cells derived from human T/NK precursor cells pT/NK-NK cells
- human CB-NK cells human CB-NK cells
- human PB-NK cells induced from hCB-HSPCs.
- RNA-seq data comparing gene expression in human pT/NK-NK cells, human CB-NK cells, and human PB-NK cells induced from hCB-HSPCs.
- NK cells and K562 cells were mixed and cultured at various E:T ratios, and the percentage of dead K562 cells was analyzed by FCM. Identification of specific markers for pT/NK cells (Example B-13).
- A Expression of CD122 (IL-2 receptor ⁇ chain) in pT/NK cells was evaluated by FCM analysis.
- B CFSE assay performed to evaluate the proliferation ability of CD122-positive cells.
- C Evaluation of the differentiation ability of CD122-positive cells into T cells and NK cells. Schematic diagram of the CAR sequence of the retroviral vector used to generate anti-CD19 CAR-NK cells and anti-HER2 CAR-NK cells derived from human pT/NK cells constructed in Example C-1.
- Example C-2 Generation of anti-CD19 CAR-NK cells and anti-HER2 CAR-NK cells from human pT/NK cell-derived NK cells (Example C-2).
- A Using the vectors shown in Figure 33, each CAR gene was introduced into human pT/NK cell-derived NK cells, and GFP-positive CAR-NK cells were isolated using a cell sorter and further expanded by co-culturing with aAPCs. After culturing, GFP expression was analyzed by FCM to confirm stable expression of the introduced gene.
- B Antigen-specific cytotoxic activity of anti-CD19 CAR-NK cells or anti-HER2 CAR-NK cells.
- Example C-3 Using the vector shown in Figure 33, anti-CD19 CAR genes or anti-HER2 CAR genes were introduced into human pT/NK cells, and pT/NK cells expressing each CAR gene were isolated and amplified using GFP expression as an indicator. Stable expression of the introduced genes was confirmed in the amplified pT/NK cells. Induction of differentiation from human pT/NK cells transfected with a CAR gene into CAR-NK cells (Example C-4).
- B The obtained CAR-NK cells were expanded by culturing in the presence of aAPC and IL-2. FCM analysis of the expanded CAR-pT/NK cell-derived CAR-NK cells confirmed the production of CAR-NK cells that stably express the transgene.
- C Approximately 1 x 104 CAR-NK cells were produced per human pT/NK cell transfected with a CAR gene. Evaluation of the cytotoxic activity of CAR-NK cells derived from pT/NK cells transfected with a CAR gene against target cells (Example C-5).
- pT/NK cell-derived anti-HER2 CAR-NK cells pT/NK-CAR-NK
- CB-CAR-NK CB-NK-derived anti-HER2 CAR-NK cells
- PB-CAR-NK PB-NK-derived anti-HER2 CAR-NK cells
- immune cell therapy refers to a method of treating a disease by utilizing the biological defense function of immune cells to reduce or remove cells or tissues that cause the disease.
- a representative immune cell therapy is CAR immune cell therapy, which treats a tumor by reducing or removing cells expressing an antigen by immune cells expressing a CAR that specifically recognizes an antigen that is specifically expressed in cells contained in tumor tissue.
- CAR immune cell therapy also includes, for example, immunotherapy targeting B cell-specific antigens for the treatment of autoimmune diseases, and immune cell therapy targeting antigens specific to bacteria or viruses to reduce or remove bacteria- or virus-infected cells for the treatment of bacterial or viral infections.
- Diseases caused by cells expressing target antigens include such various diseases, and representative examples include tumors, autoimmune diseases, bacterial infections, and viral infections.
- the term "cells expressing target antigens” includes not only the case where the target antigen is expressed from the nuclear or mitochondrial genome that the cell originally possesses, but also the case where bacteria or viruses that have infected the cell express the target antigen within the cell.
- exogenous receptor means a T cell receptor (TCR), a chimeric antigen receptor (CAR), or a chimeric autoantibody receptor (CAAR).
- TCR, CAR, or CAAR may be expressed as "TCR/CAR/CAAR”.
- cell expressing an exogenous receptor includes TCR/CAR/CAAR expressing cells (cells are, for example, multipotent blood progenitor cells, the same below), TCR/CAR expressing cells, TCR/CAAR expressing cells, CAR/CAAR expressing cells, TCR expressing cells, CAR expressing cells, and CAAR expressing cells.
- the term "antigen-specific receptor” means TCR or CAR.
- TCR or CAR may be written as "TCR/CAR”.
- the term “cell expressing an antigen-specific receptor” includes TCR/CAR expressing cells, TCR expressing cells, and CAR expressing cells.
- the expressions "TCR or CAR that specifically recognizes a tumor antigen” and "treatment of a tumor using the same" used in the present specification describe one embodiment of the use of the TCR/CAR expressing cells of the present invention, and since TCR/CAR expressing cells targeting an antigen expressed in cells other than a tumor can be used to treat diseases (e.g., autoimmune diseases, bacterial infections, etc.) that are treated by reducing or removing cells expressing the antigen, even inventions including the above description can be applied to diseases other than tumors.
- diseases e.g., autoimmune diseases, bacterial infections, etc.
- chimeric receptor means CAR or CAAR.
- CAR or CAAR may be expressed as “CAR/CAAR”.
- cell expressing a chimeric receptor includes CAR/CAAR expressing cells, CAR expressing cells, and CAAR expressing cells.
- TCR is a receptor present on the surface of T cells that is used by T cells to recognize antigens, and is composed of a dimer of ⁇ and ⁇ chains, or ⁇ and ⁇ chains.
- Most T cells are ⁇ T cells that have a TCR ( ⁇ TCR) composed of a dimer of ⁇ and ⁇ chains, and in the present invention, ⁇ TCR is usually used as the TCR expressed in immune cells.
- CAR is an artificially created receptor that can specifically recognize an antigen by linking an antigen recognition part derived from an antibody that specifically recognizes the antigen, a transmembrane domain derived from a cell surface molecule such as CD8 or CD28, one or more costimulatory domains derived from the intracellular signaling domain of a costimulatory receptor molecule such as CD28, 4-IBB, OX40, or 2B4, and an activation domain derived from the intracellular signaling domain of a CD3 ⁇ molecule.
- a short chain variable fragment (scFv) having a structure in which the heavy chain variable region (VH) and light chain variable region (VL) of an antibody that specifically recognizes a desired antigen are linked by an appropriate linker can be preferably used.
- the target antigen is not limited to tumor antigens, and various antigens can be adopted as long as they are characteristically or specifically expressed in cells that are expected to have a therapeutic effect by reducing or removing specific cells.
- CARs for antigens that are specifically expressed in B cells, such as CD19 are useful for treating not only blood cancers but also autoimmune diseases.
- the costimulatory domain can be appropriately selected depending on the type of immune cell in which the CAR is to be expressed.
- Non-Patent Document 1 reports that a domain derived from 2B4 can be used as a costimulatory domain for a CAR expressed in NK cells.
- CAAR Chomeric Auto-Antibody Receptor
- CAAR Chomeric Auto-Antibody Receptor
- CAAR differs from CAR in that the antigen recognition part in CAR is an antigen-derived part derived from an autoantigen, but the molecular structure is otherwise the same as CAR.
- the antigen-derived part is usually composed of an oligopeptide or polypeptide that contains part or all of the amino acid sequence of the autoantigen that is the cause of autoimmune disease.
- immune cells expressing CAAR bind to the B cell receptor (BCR) on the surface of pathogenic B cells that recognize autoantigens, and show a therapeutic effect on autoimmune diseases by reducing the pathogenic B cells that cause autoimmune diseases.
- BCR B cell receptor
- Examples of such autoimmune diseases and autoantigens include DSG3 in pemphigus vulgaris and the nicotinic acetylcholine receptor ⁇ subunit in myasthenia gravis.
- culture in the presence of a Notch ligand refers to culture conditions under which the Notch ligand and the cells to be cultured can come into contact with each other, thereby stimulating and enhancing the Notch signal of the cells.
- the form of the Notch ligand used may be a recombinant protein, a cell expressing the protein (e.g., feeder cells), or a culture of the cells containing the Notch ligand protein (e.g., culture supernatant, cell lysate, etc.).
- Preferred Notch ligands include Delta-like ligands such as Delta-like 1 (DLL1, human gene is Gene ID: 28514, NCBI Reference Sequence: NM_005618.4, SEQ ID NOs: 19 and 20) and Delta-like 4 (DLL4, human gene is Gene ID: 54567, NCBI Reference Sequence: NM_019074.4, SEQ ID NOs: 21 and 22).
- the amino acid sequences of DLL1 and DLL4 that can be used as Notch ligands in the present application are not limited to the sequences shown in SEQ ID NOs: 20 and 22, and proteins having amino acid sequences with 90% or more, for example 95% or more, or 98% or more identity with these sequences can also be used as DLL1 and DLL4.
- Examples of methods for culturing the above cell population in the presence of a Notch ligand include a method of culturing target cells on feeder cells expressing a Notch ligand, and a method of culturing the above cell population in a culture vessel (plate, petri dish, etc.) whose inner surface is coated with a culture of a Notch ligand protein (or a fragment thereof including at least an extracellular domain) or a feeder cell expressing a Notch ligand.
- a culture vessel plate, petri dish, etc.
- Various feeder cells that express a Notch ligand are known and can be easily obtained from cell banks, etc.
- OP9 cells OP9/DLL1 cells, etc.
- Tst-4 cells Tst-4/DLL1 cells, etc.
- S17 cells S17/DLL1 cells, etc.
- MS-5 cells MS-5/DLL1 cells, etc. in which a Notch ligand is forcibly expressed.
- culture in the absence of a Notch ligand refers to culture in a culture system that does not substantially contain a Notch ligand.
- Co-culture with feeder cells that do not substantially express a Notch ligand corresponds to culture in the absence of a Notch ligand.
- feeder cells that do not substantially express a Notch ligand may be used, but basically there is no need to use them.
- human T/NK precursor cells immature NK cells, and mature NK cells are cells defined by the following marker expression patterns, respectively. It is known that immature NK cells are phenotype-similar to NK cells isolated from umbilical cord blood (cord blood NK cells), and mature NK cells show the phenotype of NK cells isolated from peripheral blood (peripheral blood NK cells).
- Human T/NK progenitor cells CD3 negative, CD4 negative, CD8 negative, CD56 negative, CD161 negative, and CD7 positive (CD3 - CD4 - CD8 - CD56 - CD161 - CD7 + )
- Human immature NK cells CD3 negative, CD4 negative, CD8 negative, CD56 positive, CD161 positive, CD16 negative, and KIR negative (CD3 - CD4 - CD8 - CD56 + CD161 + CD16 - KIR - )
- Human mature NK cells CD3 negative, CD4 negative, CD8 negative, CD56 positive, CD161 positive, CD16 positive, and KIR positive (CD3 - CD4 - CD8 - CD56 + CD161 + CD16 + KIR + )
- CD16 and KIR killer cell immunoglobulin-like receptor
- maturation markers that indicate the maturity of human NK cells.
- NK cells As NK cells mature, the expression levels of CD16 and KIR increase.
- NK cells that are positive for CD16 and KIR the lower the expression levels of these markers, the more immature the cells are evaluated to be.
- the cultured human T/NK progenitor cells which are one of the inventions provided by the present invention, are human T/NK progenitor cells isolated from a living body and cultured, or induced to differentiate in vitro from pluripotent cells such as pluripotent blood progenitor cells, and are characterized by being CD122 positive.
- the inventors of the present application were the first to discover that CD122 is a specific marker for human T/NK progenitor cells in the Examples below.
- the cultured human T/NK progenitor cells of the present invention may further be cells that satisfy one, two, three, four, five, or six surface antigen expression conditions selected from the group consisting of CD3 negative, CD4 negative, CD8 negative, CD56 negative, CD161 negative, and CD7 positive.
- the cultured human T/NK progenitor cells of the present invention are CD122 positive and CD3 negative. In another embodiment, the cultured human T/NK progenitor cells of the present invention are CD122 positive, CD3 negative, and CD4 negative. In yet another embodiment, the cultured human T/NK progenitor cells of the present invention are CD122 positive, CD3 negative, CD4 negative, and CD8 negative. In yet another embodiment, the cultured human T/NK progenitor cells of the present invention are CD122 positive, CD3 negative, CD4 negative, CD8 negative, and CD56 negative.
- the cultured human T/NK progenitor cells of the present invention are CD122 positive, CD3 negative, CD4 negative, CD8 negative, CD56 negative, and CD161 negative. In yet another embodiment, the cultured human T/NK progenitor cells of the present invention are CD122 positive, CD3 negative, CD4 negative, CD8 negative, CD56 negative, CD161 negative, and CD7 positive.
- the expression of these surface antigen markers can be examined by well-known techniques such as a flow cytometer using antibodies against each surface antigen marker, and real-time PCR using primers and probes that detect the expression of each surface antigen marker.
- Aspect A is a method for producing TCR/CAR/CAAR-expressing immune cells by introducing an exogenous receptor gene into pluripotent blood progenitor cells and then inducing differentiation into immune cells, and includes the steps of: preparing pluripotent blood progenitor cells from a cell population containing hematopoietic stem cells; preparing pluripotent blood progenitor cells that express the exogenous receptor by introducing a gene encoding the exogenous receptor into the pluripotent blood progenitor cells; and inducing differentiation of the pluripotent blood progenitor cells that express the exogenous receptor into immune cells.
- Aspect B is a method for producing TCR/CAR/CAAR-expressing immune cells by inducing differentiation of multipotent blood progenitor cells into immune cells and then introducing an exogenous receptor gene, and includes the steps of preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells; inducing differentiation of the multipotent blood progenitor cells into immune cells; and introducing the gene encoding the exogenous receptor into the immune cells.
- Immune cells include T cells, NK cells, macrophages, and B cells.
- the exogenous receptor is a TCR
- a system has been developed that induces antigen-specific signal transduction by TCR by introducing CD3, which forms a complex with TCR and transmits TCR signals into cells, into NK cells together with the TCR (Mensali et al., eBioMed. 40. 106-117 (2019)), and this technology can be used to make TCR function in NK cells, macrophages, and B cells. Therefore, the present invention also includes the production of NK cells, macrophages, or B cells that express TCR, in which case the CD3 gene is also introduced into the cells in combination with the TCR gene.
- the exogenous receptor is a CAR
- the CAR can function in various immune cells such as NK cells, macrophages, and B cells, and can thus favorably induce differentiation into the various immune cells mentioned above.
- CAAR is a chimeric receptor that uses CAR, and like CAR, CAAR can function in various immune cells such as NK cells, macrophages, and B cells. Therefore, even when the exogenous receptor is CAAR, it can be preferably induced to differentiate into the various immune cells mentioned above.
- Multipotent blood progenitor cells are cells that have a more restricted differentiation direction than hematopoietic stem cells, but have the pluripotency to differentiate into multiple cell lineages and have the ability to self-replicate.
- iLS induced leukocyte stem cells
- T/NK progenitor cells can be preferably used as multipotent blood progenitor cells.
- a cell population containing hematopoietic stem cells can be obtained from umbilical cord blood, bone marrow fluid, or peripheral blood, and usually contains hematopoietic stem cells and hematopoietic progenitor cells.
- Human hematopoietic stem cells are determined as CD34 positive, CD59 positive, CD90/Thy1 positive, CD38 weakly positive or negative, c-Kit negative or weakly positive, and Lineage marker negative (CD34 + CD59 + CD90/Thy1 + CD38 low/- c-Kit -/low Lin - ).
- a cell population containing hematopoietic stem cells (a cell population in which hematopoietic stem cells account for approximately 3% or more, for example 7% or more) can be obtained by separating and collecting CD34+ cells using cell sorting or magnetic beads.
- the TCR/CAR/CAAR-expressing immune cells produced by the present invention when using the TCR/CAR/CAAR-expressing immune cells produced by the present invention for the treatment of tumors or autoimmune diseases, it is possible to obtain a cell population containing hematopoietic stem cells from umbilical cord blood, which is generally not derived from the patient himself, or from bone marrow fluid or peripheral blood collected from the patient, and prepare multipotent blood progenitor cells derived from the patient's own cells.
- iLS cells When the pluripotent blood progenitor cells are iLS cells, the method of preparing them is publicly known as described in Non-Patent Documents 2 and 3 and Patent Document 1, and iLS cells can be prepared by culturing a cell population containing hematopoietic stem cells under conditions that induce differentiation into B cells while inhibiting the function of the intracellular transcription factor E2A (also known as transcription factor 3 (TCF3)).
- E2A also known as transcription factor 3 (TCF3)
- Methods for inhibiting the function of E2A include, for example, enhancing a factor that binds to E2A and inhibits the action of E2A on target genes, introducing a dominant-negative mutant in which the functional domain of E2A is inactivated, and inhibiting the expression or activity of other transcription factors that are under the control of E2A or function cooperatively with E2A.
- a preferred method is to forcibly express the differentiation inhibitor Id (Inhibitor of DNA binding) in hematopoietic stem cells.
- Id protein is known to dominant-negatively inhibit E proteins such as E2A (Norton, J.D. et al., Trends Cell Biol. 8, 58-65 (1998); and Sayegh, C.E. et al., Nat. Immunol. 4, 586-593 (2003)).
- Forcibly expressing Id protein in hematopoietic stem cells can bind to E2A and inhibit E2A from acting on target genes.
- the Id factor may be any of the four types Id1 to Id4 present in mammals.
- Gene sequence information for Id1 to Id4 is registered in databases such as GenBank and is easily available.
- sequence information for the human Id1 gene is registered in GenBank under the accession numbers NM_002165 (transcript variant 1) and NM_181353 (transcript variant 2)
- sequence information for the human Id2 gene is registered under the accession numbers NM_002166
- sequence information for the human Id3 gene is registered under the accession numbers NM_002167
- sequence information for the human Id4 gene is registered under the accession numbers NM_001546.
- sequences of the human Id3 gene and protein of NM_002167 used in the examples below are shown in sequence numbers 5 and 6 in the sequence table, respectively. Based on this publicly known sequence information, appropriate primers can be designed, and RT-PCR can be performed using RNA extracted from cells or tissues expressing Id as a template to amplify DNA encoding Id.
- the obtained DNA is incorporated into an appropriate expression vector under the control of an appropriate promoter (CMV promoter, SV40 promoter, LTR promoter, etc.) that constitutively exerts strong promoter activity in mammalian cells, and then introduced into a cell population containing hematopoietic stem cells, whereby the Id protein can be forcibly expressed in the hematopoietic stem cells.
- an appropriate promoter CMV promoter, SV40 promoter, LTR promoter, etc.
- animal virus vectors such as retrovirus vectors, adenovirus vectors, and lentivirus vectors can be preferably used, but plasmid vectors for mammalian cells can also be used.
- the DNA encoding Id in order to sustain the expression of the Id factor in the cells, it is preferable to introduce the DNA encoding Id so that it is incorporated into the chromosome of the hematopoietic stem cells, and retrovirus vectors and lentivirus vectors that can incorporate the introduced gene into the chromosome can be preferably used.
- retrovirus vectors and lentivirus vectors that can incorporate the introduced gene into the chromosome can be preferably used.
- the DNA encoding Id can be incorporated into the chromosome by random integration.
- E2A inhibition by forced expression of Id factors can be exemplified by constitutive E2A inhibition, which inhibits E2A constitutively in cells, and controlled E2A inhibition, which inhibits E2A only under certain conditions.
- constitutive E2A inhibition which inhibits E2A constitutively in cells
- controlled E2A inhibition which inhibits E2A only under certain conditions.
- inducing differentiation of pluripotent blood progenitor cells into B cells after introduction of a TCR gene or CAR gene in a later step it is preferable to carry out controlled E2A inhibition so that E2A inhibition can be released.
- constitutive E2A inhibition may be used, but controlled E2A inhibition is also preferably used.
- Constitutive E2A inhibition can be achieved by expressing DNA encoding the Id factor under the control of a suitable promoter that exerts strong constitutive promoter activity in mammalian cells.
- An example of a method for controlled E2A inhibition is a system in which E2A inhibition is controlled by 4-hydroxytamoxifen (4-OHT) using the ligand-binding domain of the human estrogen receptor, as described in the following examples.
- the ID-ER gene in which the ligand-binding domain sequence of the human estrogen receptor (hER) is linked downstream of DNA encoding the Id factor, is introduced into cells, and the ID-ER protein, in which the hER ligand-binding domain is fused to the C-terminus of the Id factor, is expressed in the cells.
- Non-Patent Document 3 if 4-OHT is added to the medium and iLS cells are cultured, the iLS cells can be maintained without differentiation. When inducing differentiation into immune cells, it is not necessary to add 4-OHT to the medium, so differentiation can be induced in a medium without 4-OHT.
- the sequence of the hER ligand-binding domain the sequence from positions 370 to 1311 in the base sequence shown in SEQ ID NO: 1 can be preferably used.
- This sequence is the sequence of a mutant hER ligand-binding domain (ERT2) in which several base substitutions have been added to the ligand-binding domain sequence (positions 1078 to 2019 in SEQ ID NO: 7; the sequence of this 942-base region is shown in SEQ ID NO: 9) of hER isoform 1 (SEQ ID NO: 7) of GenBank Accession No. NM_000125.
- SEQ ID NO: 1 is the base sequence of the ID3-ERT2 gene, which is a preferred example of the ID-ER gene, in which the ERT2 sequence has been fused to the full-length cDNA of the human ID3 gene.
- the sequence encoding the hER ligand-binding domain used in the ID-ER gene is not limited to this mutant sequence, and a sequence in which 10 or fewer bases have been substituted or added in the base sequence of the ligand-binding domain of hER isoform 1 shown in SEQ ID NO: 9 can be used as the hER ligand-binding domain sequence.
- a DNA structure in which a hER ligand binding domain sequence is linked to the 3' end of the DNA encoding the Id factor via an appropriate spacer sequence can be used as the ID-ER gene.
- the ID gene (DNA encoding the Id factor) or the ID-ER gene may be linked to DNA encoding any protein that serves as a marker for gene transfer.
- a cell sorter to separate and collect cells expressing the marker protein from a cell population containing hematopoietic stem cells after gene transfer treatment, hematopoietic stem cells into which the ID gene or ID-ER gene has been introduced and which express the Id factor can be obtained.
- the cells After obtaining hematopoietic stem cells in which E2A is inhibited by the expression of Id factors, etc., the cells are cultured under conditions that induce differentiation into B cells.
- E2A inhibition When controlled E2A inhibition is performed, the cells are cultured to induce differentiation into B cells under E2A inhibition conditions (in the case of a system that utilizes the ligand-binding domain of the human estrogen receptor, in the presence of 4-OHT).
- Culture under conditions that induce differentiation into B cells means culture on feeder cells capable of supporting differentiation into B cells, with an appropriate amount of cytokines added to the medium.
- Feeder cells capable of supporting differentiation into B cells include OP9 cells, TSt-4 cells, S17 cells, MS-5 cells, etc.
- Examples of the above cytokines that can be used include IL-7, Flt3-L, SCF, etc., each at a concentration of about 0.1 to 20 ng/mL.
- the method of preparation is publicly known as described in Non-Patent Documents 2, 4, and 5.
- cytokines SCF, IL-7, and Flt3-L can be preferably used.
- pT/NK cells are vigorously expanded by adding SCF, IL-7, and Flt3-L to the medium at a concentration of 10 to 50 ng/ml, particularly a high concentration of 25 to 50 ng/ml, and culturing in the presence of Notch signal.
- SCF, IL-7, and Flt3-L it is preferable to use SCF, IL-7, and Flt3-L at a lower concentration than the above.
- pT/NK cells can be expanded in large quantities by adding the same cytokines to the culture medium at low concentrations of 1 ng/mL or more and less than 10 ng/mL, and culturing in the presence of Notch signals.
- pT/NK cells can be expanded several-fold further by further adding TPO or M-CSF to the culture medium (see Examples B-8 to B-10, etc.).
- TPO or M-CSF The production of pT/NK cells from human hematopoietic stem cells is described in detail in "II. Method for producing human T/NK precursor cells.”
- Culturing a cell population containing CD34-positive hematopoietic stem cells in the presence of a Notch ligand can stimulate and enhance the Notch signal of the hematopoietic stem cells.
- the definition of the term "culture in the presence of a Notch ligand," the form of the Notch ligand used, the Notch ligand that can be preferably used, and the method of culturing in the presence of a Notch ligand are as described above.
- the human hematopoietic stem cells used in the method may have been subjected to an expansion procedure beforehand.
- An example of such an expansion culture method is a method in which a cell population containing hematopoietic stem cells is cultured in a medium containing SCF, TPO, and G-CSF at high concentrations of 100 ng/mL or more, respectively, in the absence of a Notch ligand.
- a cell population containing hematopoietic stem cells is cultured in a medium containing SCF, TPO, and G-CSF at high concentrations of 100 ng/mL or more, respectively, in the absence of a Notch ligand.
- Such expansion culture can be applied to all methods in which a cell population containing hematopoietic stem cells is used in the present invention.
- the cell population containing hematopoietic stem cells used in the present invention may be a cell population obtained after CD34-positive hematopoietic stem cells have been expanded by the above-mentioned expansion culture.
- exogenous receptor genes into multipotent blood progenitor cells
- a gene encoding an exogenous receptor is introduced into multipotent blood progenitor cells such as iLS cells or pT/NK cells to prepare multipotent blood progenitor cells expressing the receptor.
- other genes e.g., CD3 gene may be introduced into the multipotent blood progenitor cells in addition to the exogenous receptor gene.
- the target antigen can be selected according to the use of the TCR/CAR-expressing multipotent blood progenitor cells or immune cells. When these cells are used to treat tumors, a tumor antigen is selected.
- tumor antigens include GD2 (a cell surface glycolipid specifically expressed in neuroblastoma), WT1 (a Wilms tumor gene expressed in leukemia and various solid cancers), survivin (a member of the inhibitor of apoptosis (IAP) family expressed in many solid and hematological cancers), MAGE-A3 and MAGE-A4 (expressed in many types of cancer, including melanoma, esophageal cancer, non-small cell lung cancer, head and neck cancer, and bladder cancer), and tyrosinase (a melanoma antigen ), gp100 (melanoma antigen), CEA (expressed in colon cancer), Melan-A (melanoma antigen), TRP-2 (melanoma antigen), CDK4 (cyclin-dependent kinase 4, expressed in melanoma), NY-ESO-1 (highly expressed in synovial cell sarcoma and also expressed in other tumors), HER2 (expressed in breast cancer,
- sequence information such as gene sequence and amino acid sequence is publicly known, and antibodies that specifically recognize the tumor antigen are publicly known or can be produced by standard methods.
- CAR genes can be designed and produced using the variable region sequences of antibodies that specifically recognize the tumor antigen. Regardless of the type of antigen, when expressing a CAR in cells of human origin, it is preferable to use domains derived from human proteins for the intracellular domains of the CAR (costimulatory domain and activation domain).
- TCR genes that recognize a desired antigen can be obtained from antigen-specific killer T cell clones.
- a killer T cell clone specific to a desired antigen can be obtained by incorporating a desired antigen protein or its CTL epitope peptide into an antigen-presenting cell such as a dendritic cell to prepare an antigen-presenting cell that presents the CTL epitope peptide on its cell surface, and then co-culturing this antigen-presenting cell with a T cell to bring the two into contact with each other.
- the TCR gene can be prepared by PCR amplification from such an expression vector.
- antigens other than tumor antigens include viral antigens and parasitic antigens.
- viral antigens include the constituent proteins of viruses such as hepatitis viruses (HBV, HCV, etc.), human papillomavirus, and human immunodeficiency virus, while examples of parasitic antigens include malaria parasite proteins.
- Information on the gene sequences and amino acid sequences of these antigens is also publicly known, so it is possible to obtain TCR or CAR genes that specifically recognize these antigens in a manner similar to that described above.
- CAAR When the exogenous receptor is CAAR, multipotent blood progenitor cells or immune cells expressing CAAR can be used to treat autoimmune diseases.
- the autoantigen used in the antigen-derived portion of CAAR can be selected from various autoantigens known to cause autoimmune diseases. Representative examples of autoimmune diseases and autoantigens are as described above, but are not limited to these.
- the antigen-derived portion of CAAR can be designed based on DSG3 in the case of treating pemphigus vulgaris, and based on the nicotinic acetylcholine receptor ⁇ subunit in the case of treating myasthenia gravis.
- exogenous receptor genes or CD3 genes into pluripotent blood progenitor cells can be basically performed in the same manner as the introduction of ID genes or ID-ER genes into hematopoietic stem cells.
- the efficiency of gene introduction can be improved by using the Gibbon-ape leukemia virus (GALV) envelope as the viral envelope when introducing genes using a viral vector.
- GALV Gibbon-ape leukemia virus
- a TCR/CAR/CAAR gene-expressing virus having a GALV envelope is prepared, and this is then infected into pT/NK cells by the spin-infection method or the like.
- a protein having an amino acid sequence having 90% or more, for example 95% or more, or 98% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 16 or 24 can be used as the GAVL envelope.
- the amino acid sequence shown in SEQ ID NO:24 is the amino acid sequence encoded by the envelope gene (SEQ ID NO:23) of the GALV SEATO strain registered in GenBank under AF055060.1.
- the amino acid sequence shown in SEQ ID NO:16 is the amino acid sequence encoded by the synthetic gene GALV-MTR (SEQ ID NO:15) of the GALV envelope, which has been synthesized by replacing the membrane and cytoplasmic domains of the GALV envelope (residues 627-685 in the amino acid sequence shown in SEQ ID NO:24) with the membrane and cytoplasmic domains of the Mouse Leukemia virus (MuLV) envelope to increase the efficiency of insertion of the GALV envelope protein into the virus particle (Caeser et al. Nat Commun. 2019 Oct 4;10(1)4543).
- GALV-MTR SEQ ID NO:15
- Cells expressing a marker protein linked to an introduced gene can be separated and collected using a cell sorter to isolate cells expressing the receptor to which an exogenous receptor gene has been introduced.
- the isolated receptor-expressing cells are cultured and expanded while maintaining their pluripotent state, with appropriate changes of medium and feeder cells.
- an exogenous receptor gene is introduced into iLS cells produced by controlled E2A inhibition, gene introduction, isolation, and amplification are performed while culturing iLS cells under E2A inhibition conditions.
- E2A inhibition is controlled by 4-OHT
- receptor gene introduction, isolation, and amplification are performed using medium containing 4-OHT.
- the expanded TCR/CAR/CAAR-expressing multipotent blood progenitor cells are induced to differentiate into immune cells such as T cells, NK cells, macrophages, or B cells.
- immune cells such as T cells, NK cells, macrophages, or B cells.
- iLS cells generated by controlled E2A inhibition it is not necessary to continue the E2A inhibition conditions in this step.
- a medium containing 4-OHT may be used at the start of the differentiation induction treatment, but thereafter, a medium not containing 4-OHT may be used to proceed with the differentiation induction treatment.
- the multipotent blood progenitor cells When the multipotent blood progenitor cells are iLS cells, they can be induced to differentiate into various immune cells such as T cells, NK cells, macrophages, and B cells.
- pT/NK cells have the ability to differentiate into T cells, NK cells, and myeloid cells (macrophages, etc.), but not into B cells, so when the multipotent blood progenitor cells are pT/NK cells, they are induced to differentiate into T cells, NK cells, or macrophages, preferably NK cells or macrophages, and particularly preferably NK cells.
- iLS cells are preferably used when producing TCR-expressing T cells (TCR-T cells) and CAR-expressing T cells (CAR-T cells), and pT/NK cells and iLS cells, particularly pT/NK cells, are preferably used when producing NK cells expressing CAR or CAAR (CAR-NK cells, CAAR-NK cells) and macrophages expressing CAR or CAAR (CAR-macrophages, CAAR-macrophages).
- the TCR/CAR/CAAR-expressing multipotent blood progenitor cells are TCR-expressing iLS cells, which are induced to differentiate into T cells to obtain TCR-T cells.
- the TCR/CAR/CAAR-expressing multipotent hematopoietic progenitor cells are CAR-expressing iLS cells and are induced to differentiate into T cells, NK cells, macrophages, or B cells to obtain CAR-T cells, CAR-NK cells, CAR-macrophages, or CAR-expressing B cells (CAR-B cells), or are induced to differentiate into T cells, NK cells, or macrophages to obtain CAR-T cells, CAR-NK cells, or CAR-macrophages.
- the TCR/CAR/CAAR-expressing multipotent blood progenitor cells are CAAR-expressing iLS cells, and are induced to differentiate into T cells, NK cells, macrophages, or B cells to obtain CAAR-T cells, CAAR-NK cells, CAAR-macrophages, or CAAR-B cells, or are induced to differentiate into T cells, NK cells, or macrophages to obtain CAAR-T cells, CAAR-NK cells, or CAAR-macrophages.
- the TCR/CAR/CAAR-expressing multipotent blood progenitor cells are TCR/CAR/CAAR-expressing pT/NK and are induced to differentiate into T cells to obtain TCR/CAR/CAAR-T cells.
- the TCR/CAR/CAAR-expressing multipotent blood progenitor cells are CAR-expressing pT/NK and are induced to differentiate into NK cells to obtain CAR-NK cells.
- the TCR/CAR/CAAR-expressing multipotent blood progenitor cells are CAAR-expressing pT/NK cells, which are induced to differentiate into NK cells to obtain CAAR-NK cells.
- the TCR/CAR/CAAR-expressing multipotent blood progenitor cells are CAR-expressing pT/N cells K, which are induced to differentiate into macrophages to obtain CAR-macrophages.
- the TCR/CAR/CAAR-expressing multipotent blood progenitor cells are CAAR-expressing pT/NK cells, which are induced to differentiate into macrophages to obtain CAAR-macrophages.
- the TCR/CAR/CAAR-expressing multipotent blood progenitor cells are TCR-expressing iLS cells, which further express CD3.
- the cells are induced to differentiate into NK cells, macrophages, or B cells to obtain TCR-expressing NK cells, TCR-expressing macrophages, or TCR-expressing B cells (all of which also express CD3), or induced to differentiate into NK cells or macrophages to obtain TCR-expressing NK cells or TCR-expressing macrophages (all of which also express CD3).
- the TCR/CAR/CAAR-expressing multipotent blood progenitor cells are TCR-expressing pT/NK cells, which further express CD3.
- the cells are induced to differentiate into NK cells or macrophages to obtain TCR-expressing NK cells or TCR-expressing macrophages.
- TCR/CAR/CAAR-expressing multipotent blood progenitor cells into T cells In the induction of differentiation of TCR, CAR, or CAAR-expressing multipotent blood progenitor cells into T cells, first, an appropriate amount of cytokines is added to the medium and cultured in a state in which the Notch signal is stimulated, i.e., in the presence of a Notch ligand.
- the method of stimulating the Notch signal is as described above, and includes a method of culturing on feeder cells expressing a Notch ligand (specific examples of such feeder cells are as described above) and a method of culturing in a culture vessel whose inner surface is coated with a Notch ligand protein (or a fragment thereof including at least the extracellular domain).
- cytokines for example, IL-7, Flt3-L, etc. can be used at a concentration of about 0.1 to 10 ng/mL each.
- the culture is continued while appropriately changing the medium and, if feeder cells are used, changing the feeder cells.
- CD4/CD8 double positive (DP) cells which are immature T cells, are generated about three weeks after the start of induction.
- DP cells can be induced to differentiate into CD8-positive killer T cells (cytotoxic T cells) by TCR stimulation.
- Methods for TCR stimulation of DP cells include treating DP cells with anti-CD3 and anti-CD28 antibodies, and, in the case where the exogenous receptor is an antigen-specific receptor, co-culturing DP cells with antigen-presenting cells (such as dendritic cells) that present the antigen recognized by the introduced antigen-specific receptor.
- antigen-presenting cells such as dendritic cells
- the introduced exogenous receptor is a CAR or CAAR that uses the intracellular signaling domain of the costimulatory receptor molecule derived from 4-IBB
- a method of treating DP cells with anti-CD3 and anti-4-IBB antibodies can also be used.
- CD8-positive CAR-T cells or CD8-positive CAAR-T cells can be generated and expanded by TCR stimulation of DP cells by any of the above methods in a medium containing an appropriate cytokine (IL-7, IL-15, IL-2, etc.).
- an appropriate cytokine IL-7, IL-15, IL-2, etc.
- CAR/CAAR-NK cells can be generated by culturing them in a medium containing appropriate cytokines (e.g., IL-15 and IL-2) on feeder cells capable of supporting differentiation into B cells or under feeder-free conditions.
- cytokines e.g., IL-15 and IL-2
- CAR/CAAR-NK cells can be generated by culturing in a medium containing an appropriate cytokine (e.g., IL-7, Flt3-L, SCF, IL-15).
- a cytokine e.g., IL-7, Flt3-L, SCF, IL-15.
- This culture may or may not contain a Notch ligand.
- the culture is performed in the absence of a Notch ligand.
- the induction of differentiation of multipotent blood progenitor cells expressing TCR and CD3 into NK cells can be carried out in the same manner as the induction of differentiation of multipotent blood progenitor cells expressing CAR or CAAR into NK cells.
- CAR/TCR/CAAR-NK cells have sufficient proliferation ability, but if desired, their proliferation ability may be further enhanced by receptor stimulation.
- CAR/TCR/CAAR-NK cells can be receptor stimulated by, for example, co-culturing the CAR/TCR-NK cells with the K562 leukemia cell line that expresses membrane-bound IL-21 (memIL-21) and 4-1BB ligand (41BBL), or by culturing the CAR/TCR/CAAR-NK cells in the presence of cytokines such as IL-12, IL-15, IL-18, IL-21, and IL-2.
- cytokines such as IL-12, IL-15, IL-18, IL-21, and IL-2.
- macrophages expressing CAR or CAAR can be generated by culturing the cells on OP9 cells in a medium containing appropriate cytokines (e.g., SCF, M-CSF, IL-3, and IL-6).
- cytokines e.g., SCF, M-CSF, IL-3, and IL-6.
- the induction of differentiation of multipotent blood progenitor cells expressing TCR and CD3 into macrophages can be carried out in the same manner as the induction of differentiation of multipotent blood progenitor cells expressing CAR or CAAR into macrophages.
- CAR/TCR/CAAR-macrophages have sufficient proliferation ability, but if desired, their proliferation ability can be further enhanced by receptor stimulation.
- CAR/TCR/CAAR-macrophages can be receptor stimulated by, for example, culturing them in the presence of M-CSF or GM-CSF.
- CAR/CAAR-B cells can be generated by culturing them on OP9 cells in a medium containing appropriate cytokines (e.g., IL-7 and SCF).
- cytokines e.g., IL-7 and SCF.
- the induction of differentiation of multipotent blood progenitor cells expressing TCR and CD3 into B cells can be carried out in the same manner as the induction of differentiation of multipotent blood progenitor cells expressing CAR or CAAR into B cells.
- I-4 Induction of differentiation of multipotent blood progenitor cells into immune cells (Aspect B)
- the prepared multipotent blood progenitor cells are induced to differentiate into immune cells. This differentiation can be basically performed by the same method as in I-3.
- iLS cells can be induced to differentiate into various immune cells such as T cells, NK cells, macrophages, and B cells
- pT/NK cells are induced to differentiate into T cells, NK cells or macrophages, preferably NK cells or macrophages, and particularly preferably NK cells
- iLS cells are preferably used when producing TCR-expressing T cells (TCR-T cells), CAR-expressing T cells (CAR-T cells), and CAAR-expressing T cells (CAAR-T cells)
- pT/NK and iLS cells, particularly pT/NK cells are preferably used when producing NK cells expressing CAR or CAAR (CAR-NK cells, CAAR-NK cells) and macrophages expressing CAR or CAAR (CAR-macrophages, CAAR-macrophages).
- the multipotent blood progenitor cells are iLS cells and are induced to differentiate into T cells.
- a TCR gene is introduced.
- the multipotent blood progenitor cells are iLS cells and are induced to differentiate into T cells, NK cells, macrophages or B cells, or are induced to differentiate into T cells, NK cells or macrophages.
- a CAR gene is introduced.
- the multipotent blood progenitor cells are iLS cells and are induced to differentiate into T cells, NK cells, macrophages or B cells, or are induced to differentiate into T cells, NK cells or macrophages.
- the CAAR gene is introduced.
- the multipotent blood progenitor cells are pT/NK cells and are induced to differentiate into T cells.
- a TCR gene is introduced.
- the multipotent blood progenitor cells are pT/NK cells and are induced to differentiate into NK cells.
- a CAR gene is introduced.
- the multipotent blood progenitor cells are pT/NK cells and are induced to differentiate into NK cells.
- the CAAR gene is introduced.
- the multipotent blood progenitor cells are pT/NK cells and are induced to differentiate into macrophages.
- a CAR gene is introduced.
- the multipotent blood progenitor cells are pT/NK cells and are induced to differentiate into macrophages.
- the CAAR gene is introduced.
- the multipotent blood progenitor cells are iLS cells and are induced to differentiate into NK cells, macrophages or B cells, or induced to differentiate into NK cells or macrophages.
- the TCR gene is introduced and the CD3 gene is further introduced.
- the multipotent blood progenitor cells are pT/NK cells, and are induced to differentiate into NK cells or macrophages.
- the TCR gene is introduced and the CD3 gene is further introduced.
- TCR stimulation receptor stimulation in the case of T cells
- an exogenous receptor gene is introduced into the immune cells after receptor stimulation.
- an animal virus vector such as a retrovirus vector or a lentivirus vector can be preferably used, as explained in the method for preparing iLS cells in I-1.
- the CD3 gene may also be introduced simultaneously with the exogenous receptor gene.
- T cells When introducing TCR/CAR/CAAR genes into T cells, T cells are stimulated with TCR using anti-CD3 antibody (anti-CD28 antibody may also be added) and IL-2 to proliferate, and then the TCR/CAR/CAAR genes are introduced using a viral vector by spin-infection or other methods.
- anti-CD3 antibody anti-CD28 antibody may also be added
- IL-2 IL-2
- NK cells When introducing CAR/CAAR genes or TCR genes and CD3 genes into NK cells, NK cells are receptor stimulated and proliferated by co-culturing them with K562 leukemia cell lines expressing membrane-bound IL-21 (memIL-21) and 4-1BB ligand (41BBL) in the presence of appropriate cytokines (IL-2 alone, or IL-2, IL-15 and IL-21). Then, genes are introduced using a viral vector by spin-infection or other methods.
- memIL-21 membrane-bound IL-21
- 4-1BB ligand 41BBL
- the macrophages When introducing CAR/CAAR genes or TCR genes and CD3 genes into macrophages, the macrophages are receptor stimulated with M-CSF or GM-CSF to proliferate, and then the genes are introduced using a viral vector by spin-infection or other methods.
- CAR/CAAR genes or TCR genes and CD3 genes When introducing CAR/CAAR genes or TCR genes and CD3 genes into B cells, the cells are proliferated by receptor stimulation using cytokines such as IL-7 and SCF, or CD40 ligand, depending on the differentiation stage, and then the genes are introduced using a viral vector by spin-infection or other methods.
- cytokines such as IL-7 and SCF, or CD40 ligand
- receptor stimulation may be continued for a certain period of time (several days to several weeks).
- the exogenous receptor is an antigen-specific receptor
- preferred examples of the antigen recognized by the receptor specific examples of autoantigens to be used in the antigen-derived portion when the exogenous receptor is a CAAR
- methods for designing the CAR gene or CAAR gene and methods for preparing the TCR gene are as described in I-2.
- the present invention provides a novel method for producing human T/NK precursor cells that achieves improved expansion efficiency in the expansion of human T/NK precursor cells as compared to the method described in Non-Patent Document 2, which was applied to mouse cells; a method for producing T cells or NK cells that includes a step of inducing differentiation of T/NK precursor cells produced by the novel production method into T cells or NK cells; and a method for producing T cells or NK cells expressing an exogenous receptor, which combines the novel production method with the step of expressing the exogenous receptor described above.
- the method for producing human T/NK precursor cells includes a step of culturing a cell population containing human hematopoietic stem cells in a medium containing SCF, Flt3-L, and IL-7 at concentrations of 1 ng/mL or more and less than 10 ng/mL, respectively, in the presence of a Notch ligand (hereinafter, the medium used in this step is referred to as the "human pT/NK cell induction medium").
- the human pT/NK cell induction medium employs the above-mentioned low concentrations of SCF, Flt3-L, and IL-7, making it possible to generate and expand a large number of human pT/NK cells. Furthermore, when at least one of TPO and M-CSF is added at a predetermined concentration to the human pT/NK cell induction medium, the production amount of human pT/NK cells can be further increased several-fold.
- the human cell population containing human hematopoietic stem cells used in the method for producing human pT/NK cells can be as described in I-1.
- the human cell population can be a cell population after the above-mentioned expansion culture.
- the culture in the presence of a Notch ligand is also as described above, and the Notch ligand and culture conditions described in I-1. can be appropriately adopted.
- the Notch ligand a recombinant protein can be adopted, or feeder cells expressing a Notch ligand can be adopted.
- the concentrations of SCF, Flt3-L and IL-7 contained in the human pT/NK cell induction medium can be appropriately selected within the range of 1 ng/mL or more and less than 10 ng/mL. All three may be at the same concentration, or some or all of the three may be at different concentrations within the above range. Preferably, each is at a concentration appropriately selected from the range of 3 to 7 ng/mL, more preferably each is at a concentration appropriately selected from the range of 4 to 6 ng/mL, and even more preferably each is at about 5 ng/mL.
- the concentration of TPO contained in the human pT/NK cell induction medium can be appropriately selected in the range of 1 to 100 ng/mL.
- the TPO concentration may be, for example, 1 to 80 ng/mL, 1 to 70 ng/mL, 1 to 60 ng/mL, 1 to 55 ng/mL, 1 to 50 ng/mL, 5 to 80 ng/mL, 5 to 70 ng/mL, 5 to 60 ng/mL, 5 to 55 ng/mL, 5 to 50 ng/mL, 10 to 80 ng/mL, 10 to 70 ng/mL, 10 to 60 ng/mL, 10 to 55 ng/mL, or 10 to 50 ng/mL.
- the concentration of M-CSF contained in the human pT/NK cell induction medium can be appropriately selected in the range of 1 to 100 ng/mL.
- the M-CSF concentration may be, for example, 1 to 50 ng/mL, 1 to 40 ng/mL, 1 to 30 ng/mL, 5 to 50 ng/mL, 5 to 40 ng/mL, 5 to 30 ng/mL, 5 to 25 ng/mL, 7 to 50 ng/mL, 7 to 40 ng/mL, 7 to 30 ng/mL, or 7 to 25 ng/mL.
- the human pT/NK cell induction medium may contain either TPO or M-CSF, or may contain both.
- Particularly preferred examples of the medium include media containing SCF, Flt3-L, and IL-7 at concentrations of 4-6 ng/mL or 5 ng/mL, respectively, and TPO at concentrations of 10-55 ng/mL or 10-50 ng/mL.
- the medium used in the method of the present invention can be any medium used for normal cell culture or a medium prepared for the culture of hematopoietic cells, without any particular limitations.
- Representative media used in general cell culture include IMDM (Iscove's Modified Dulbecco's Medium), ⁇ MEM (alpha Modified Eagle's Minimum Essential Medium), DMEM (Dulbecco's Modified Eagle's Medium), Ham's Nutrient Mixture F12, McCoy's 5A Medium, EMEM (Eagle's Minimum Essential Medium), and RPMI1640 medium.
- serum-free media suitable for culturing hematopoietic cells include StemPro34 (Invitrogen), Stemline (Sigma-Aldrich), Stemline II (Sigma-Aldrich), X-VIVO 10 (Lonza), X-VIVO 15 (Lonza), X-VIVO 20 (Lonza), HPGM (Lonza), StemSpan H3000 (Stem Cell Technology), StemSpanSFEM (Stem Cell Technology), and QBSF-60 (Quality Biologicals).
- the cells may be cultured under serum-free conditions, or under conditions supplemented with serum such as FBS or a serum substitute such as Knockout Serum Replacement (Gibco).
- the culture period is not particularly limited, but is, for example, 7 to 56 days (preferably 28 to 42 days), and the medium is preferably replaced with fresh medium at intervals of 1 to 7 days (preferably 3 to 4 days).
- the culture temperature is, for example, 35 to 39°C, and the culture can be performed in the presence of 0 to 10% CO2 .
- the culture in the presence of a Notch ligand may be performed using a method that uses feeder cells that express a Notch ligand, or may be performed using another method that uses a culture vessel whose inner surface is coated with a Notch ligand protein or the like.
- the method for producing human NK cells includes the steps of producing human T/NK precursor cells by the human pT/NK cell production method, and inducing differentiation of human NK cells by culturing the produced human T/NK precursor cells in a medium containing IL-7, Flt3-L, SCF and IL-15 in the absence of a Notch ligand.
- a medium containing IL-7, Flt3-L, SCF and IL-15 in the absence of a Notch ligand.
- IL-7, Flt3-L, SCF and IL-15 can each be used at about 1-50 ng/ml, for example, about 5-30 ng/ml.
- IL-15 and Flt3-L can each be used at about 1-30 ng/ml or about 5-20 ng/ml
- SCF and IL-15 can each be used at about 5-50 ng/ml or about 10-40 ng/ml.
- Human NK cells obtained by the above-mentioned human pT/NK cell production method maintain a juvenile state and exhibit a characteristic surface antigen profile.
- the present invention also provides cultured human NK cells characterized by such surface antigens.
- the cultured human NK cells provided by the present invention are characterized by being immature and less exhausted than human cord blood NK cells isolated from human umbilical cord blood, due to lower expression of CD16 and KIR (killer cell immunoglobulin-like receptor), which are indicators of maturity, and lower expression of the exhaustion marker TIGIT (T cell immunoreceptor with Ig and ITIM domains; NCBI Gene ID: 201633, NCBI Reference Sequence: NM_173799.4).
- human cord blood NK cells are known to be immature in maturity compared to other human NK cells such as human peripheral blood NK cells, but as shown in Example B-11 below, human NK cells induced from human T/NK precursor cells produced by the human pT/NK cell production method of the present invention are even immature than human cord blood NK cells.
- the cultured human NK cells of the present invention are also characterized by a lower expression of the exhaustion marker TIGIT, which is an indicator of the degree of exhaustion of NK cells, than human cord blood NK cells, and thus a lower degree of exhaustion.
- the cultured human NK cells of the present invention are cells with characteristics different from human NK cells naturally occurring in the human body.
- the expression levels of CD16, KIR, and TIGIT in the cultured human NK cells of the present invention may be independently 1/2 or less, 1/3 or less, 1/4 or less, 1/5 or less, 1/6 or less, 1/7 or less, or 1/8 or less of the expression levels in human cord blood NK cells.
- KIR includes KIR2DL2 (killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2; NCBI Gene ID: 3803, NCBI Reference Sequence: NM_014219.3) and KIR2DL3 (killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3; NCBI Gene ID: 3804, NCBI Reference Sequence: NM_015868.3).
- Expression of KIR in the cultured human NK cells of the present invention may be either expression of KIR2DL2 or expression of KIR2DL3, or may be expression of both.
- the cultured human NK cells of the present invention may further be characterized by higher expression of one, two, three, four or five genes selected from CCR3, CCR6, CCR7, CCR8 and CCR9 compared to human umbilical cord blood NK cells and human peripheral blood NK cells.
- the expression of surface antigen markers CD3, CD4, CD8, CD56 and CD161 of the cultured human NK cells of the present invention is similar to that of other human NK cells, being CD3 negative, CD4 negative, CD8 negative, CD56 positive and CD161 positive.
- the expression of these surface antigen markers can be examined by well-known techniques such as flow cytometry using antibodies against each surface antigen marker, and real-time PCR using primers and probes to detect the expression of each surface antigen marker.
- the production method of the immune cell therapy agent for tumors or autoimmune diseases includes production method 1 for producing CD8-positive cytotoxic TCR-T, CAR-T or CAAR-T cells as the immune cell therapy agent, and production method 2 for producing CAR-NK cells, CAAR-NK cells, CAR-macrophages or CAAR-macrophages as the immune cell therapy agent.
- Production method 1 and production method 2 each include two methods: a method for producing each receptor-expressing cell by the method of embodiment A above, and a method for producing each receptor-expressing cell by the method of embodiment B above.
- Production method 1A is a method for producing CD8-positive cytotoxic TCR-T, CAR-T or CAAR-T cells by the method for producing TCR/CAR/CAAR-expressing immune cells of aspect A, in which an exogenous receptor gene is introduced into multipotent blood progenitor cells and then the cells are induced to differentiate into immune cells, and using the cells as an immune cell therapy agent for tumors or autoimmune diseases, and includes the following steps 1A-1 to 1A-5.
- Step 1A-1 preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells.
- Step 1A-2 is to prepare multipotent blood progenitor cells expressing an exogenous receptor, which is a TCR or CAR that specifically recognizes a CAAR or a tumor antigen, by introducing a gene encoding the exogenous receptor into the multipotent blood progenitor cells.
- Step 1A-3 is to prepare T cells expressing the exogenous receptor (TCR-T, CAR-T or CAAR-T cells) by inducing differentiation of the multipotent blood progenitor cells expressing the exogenous receptor into T cells.
- Step 1A-5 is to prepare CD8-positive cytotoxic TCR-T or CAR-T cells as an immune cell therapy agent for a tumor expressing the above-mentioned tumor antigen, or to prepare CD8-positive cytotoxic CAR-T cells as an immune cell therapy agent for an autoimmune disease.
- Manufacturing method 1B is a method for producing CD8-positive cytotoxic TCR-T, CAR-T or CAAR-T cells by the method for producing TCR/CAR/CAAR-expressing immune cells of aspect B, in which multipotent blood progenitor cells are induced to differentiate into immune cells and then an exogenous receptor gene is introduced, and using the cells as an immune cell therapy agent for tumors or autoimmune diseases, and includes the following steps 1B-1 to 1B-4.
- Step 1B-1 preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells.
- Step 1B-2 inducing differentiation of multipotent blood progenitor cells into T cells.
- Step 1B-3 is to prepare CD8-positive cytotoxic TCR-T, CAR-T or CAAR-T cells by introducing a gene encoding an exogenous receptor, which is a TCR or CAR that specifically recognizes a CAAR or a tumor antigen, after TCR stimulation of the T cells.
- Step 1B-4 is to prepare CD8-positive cytotoxic TCR-T or CAR-T cells as an immune cell therapy agent for a tumor expressing the above-mentioned tumor antigen, or to prepare CD8-positive cytotoxic CAR-T cells as an immune cell therapy agent for an autoimmune disease.
- Production method 2A is a method in which CAR-NK cells, CAAR-NK cells, CAR-macrophages or CAAR-macrophages are produced by the TCR/CAR/CAAR-expressing immune cell production method of aspect A, in which an exogenous receptor gene is introduced into multipotent blood progenitor cells and then the cells are induced to differentiate into immune cells, and the produced cells are used as an immune cell therapy agent for tumors or autoimmune diseases, and the method comprises the following steps 2A-1 to 2A-4.
- Step 2A-1 preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells.
- Step 2A-2 is to prepare multipotent blood progenitor cells expressing a chimeric receptor, which is a CAAR or a CAR that specifically recognizes a tumor antigen, by introducing a gene encoding the chimeric receptor into the multipotent blood progenitor cells.
- step 2A-3 of preparing NK cells (CAR-NK or CAAR-NK cells) or macrophages (CAR-macrophages or CAAR-macrophages) expressing the chimeric receptor by inducing differentiation of multipotent blood progenitor cells expressing the chimeric receptor into NK cells or macrophages.
- Step 2A-4 in which CAR-NK cells or CAR-macrophages are prepared as an immune cell therapy for a tumor expressing the above-mentioned tumor antigen, or CAAR-NK cells or CAAR-macrophages are prepared as an immune cell therapy for an autoimmune disease.
- CAR/CAAR-NK cells and CAR/CAAR-macrophages have sufficient proliferation ability even before receptor stimulation, so they can be prepared as immune cell therapy agents without receptor stimulation and administered to patients.
- a step of receptor-stimulating the prepared CAR/CAAR-NK cells or CAR/CAAR-macrophages may be carried out after step 2A-3.
- step 2A-4 the CAR/CAAR-NK cells or CAR/CAAR-macrophages after receptor stimulation are prepared as immune cell therapy agents.
- Manufacturing method 2B is a method in which CAR-NK cells, CAAR-NK cells, CAR-macrophages or CAAR-macrophages are produced by the TCR/CAR/CAAR-expressing immune cell production method of aspect B, in which multipotent blood progenitor cells are induced to differentiate into immune cells and then an exogenous receptor gene is introduced, and the produced cells are used as an immune cell therapy agent for tumors or autoimmune diseases, and includes the following steps 2B-1 to 2B-4.
- Step 2B-1 preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells.
- Step 2B-2 inducing differentiation of multipotent blood progenitor cells into NK cells or macrophages.
- Step 2B-3 is to stimulate the receptor of NK cells or macrophages, and then introduce a gene encoding a chimeric receptor that is a CAR that specifically recognizes a CAAR or a tumor antigen, thereby preparing NK cells (CAR-NK or CAAR-NK cells) or macrophages (CAR-macrophages or CAAR-macrophages) that express the chimeric receptor.
- Step 2B-4 in which CAR-NK cells or CAR-macrophages are prepared as an immune cell therapy for tumors expressing the above-mentioned tumor antigen, or CAAR-NK cells or CAAR-macrophages are prepared as an immune cell therapy for autoimmune diseases.
- the CAR/CAAR-NK cells or CAR/CAAR-macrophages obtained in step 2B-3 already have high proliferation ability and can be suitably prepared into an immune cell therapy agent without further receptor stimulation.
- Steps 1A-1 to 1A-4 of manufacturing method 1A, and steps 2A-1 to 2A-3 of manufacturing method 2A, and the step of receptor-stimulating CAR/CAAR-NK cells or CAR/CAAR-macrophages can be carried out as described in I-1. to I-3.
- Steps 1B-1 to 1B-3 of manufacturing method 1B and steps 2B-1 to 2B-3 of manufacturing method 2B can be carried out as described in I-1, I-4, and I-5.
- steps 1A-5, 1B-4, 2A-4, and 2B-4 are steps for preparing (formulating) cells expressing an exogenous receptor or a chimeric receptor as an immune cell therapy for a tumor expressing a tumor antigen specifically recognized by the receptor (when the receptor is TCR or CAR), or as an immune cell therapy for an autoimmune disease (when the receptor is CAAR).
- Receptor-expressing cells are generally administered to patients with tumors or autoimmune diseases by intravenous administration, intraperitoneal administration, or intratumoral administration (in the case of tumor patients), and therefore can be formulated as an intravenous infusion, infusion, injection, or the like, containing cells in a medium suitable for these administration routes.
- an aqueous medium e.g., high-purity sterilized water
- aqueous medium e.g., high-purity sterilized water
- human serum albumin about 0.2 to 0.5% sodium chloride, about 3 to 8% dimethyl sulfoxide as a cryoprotectant, or the like
- the number of receptor-expressing cells in a single administration can be appropriately determined depending on the type of cell, the type of tumor, etc., and can be, for example, about 1 x 10 5 to 1 x 10 9 viable cells.
- the above-mentioned manufacturing method of the present invention can produce immune cell therapy agents for tumors containing TCR-T cells, immune cell therapy agents for tumors containing CAR-T cells, immune cell therapy agents for tumors containing CAR-NK cells, immune cell therapy agents for tumors containing CAR-macrophages, immune cell therapy agents for autoimmune diseases containing CAAR-NK cells, and immune cell therapy agents for autoimmune diseases containing CAAR-macrophages.
- Each of these cellular immunotherapy agents can be used alone to treat tumors or autoimmune diseases.
- an immune cell therapy agent for tumors containing CAR-macrophages can be administered to a tumor patient in combination with one or more immune cell therapy agents including TCR-T cells, CAR-T cells, or CAR-NK cells.
- the exogenous receptors expressed by the immune cells of each immune cell therapy agent may all be receptors that recognize the same tumor antigen, or some or all of the receptors may recognize different tumor antigens.
- administered in combination means that multiple agents are administered to a patient simultaneously, sequentially, or separately. Sequential administration refers to administering the next agent immediately after administration of one agent is completed. Separate administration refers to administering multiple agents at intervals, for example, on the same day with an interval of several hours or more, or on different days during one course of treatment. When administering multiple immune cell therapy agents in combination, it is preferable to administer them to the patient sequentially or separately.
- immune cell therapy agents that are effective against various tumors that express tumor antigens, as well as immune cell therapy agents that are effective against autoimmune diseases for which autoantigens have been identified.
- tumors that express tumor antigens are as described above, and immune cell therapy agents can be produced for various solid cancers, including neuroblastoma, melanoma, esophageal cancer, lung cancer such as non-small cell lung cancer, head and neck cancer, bladder cancer, colon cancer, synovial cell sarcoma, breast cancer, ovarian cancer, and pancreatic cancer, as well as various blood cancers, including leukemia.
- autoimmune diseases and autoantigens are as described above, and immune cell therapy agents can be produced for various autoimmune diseases, including pemphigus vulgaris and myasthenia gravis. Furthermore, as described above, according to the present invention, it is possible to produce immune cell therapy agents that are effective against infectious diseases.
- Patients treated with immune cell therapy agents are primarily humans, but various animals with tumors, including other mammals, can also be treated.
- the method for treating tumors or autoimmune diseases according to the present invention is a method for treating tumors or autoimmune diseases using an immune cell therapy agent produced as described above, and has the following aspects.
- Treatment method 1a is a method for treating a tumor or an autoimmune disease by producing CD8-positive cytotoxic TCR-T, CAR-T or CAAR-T cells by the method for producing TCR/CAR/CAAR-expressing immune cells of aspect A, in which an exogenous receptor gene is introduced into multipotent blood progenitor cells and then the cells are induced to differentiate into immune cells, and administering the cells to a patient, and comprises the following steps 1a-1 to 1a-5.
- Step 1a-1 preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells.
- Step 1a-2 is to prepare multipotent blood progenitor cells expressing an exogenous receptor, which is a TCR or CAR that specifically recognizes a CAAR or a tumor antigen, by introducing a gene encoding the exogenous receptor into the multipotent blood progenitor cells. and step 1a-3 of inducing differentiation of multipotent blood progenitor cells expressing the exogenous receptor into T cells, thereby preparing TCR-T, CAR-T or CAAR-T cells, which are T cells expressing the exogenous receptor. Step 1a-4 of stimulating TCR-T, CAR-T or CAAR-T cells with TCR and inducing differentiation into CD8-positive cytotoxic TCR-T, CAR-T or CAAR-T cells.
- an exogenous receptor which is a TCR or CAR that specifically recognizes a CAAR or a tumor antigen
- Step 1a-5 is administering CD8-positive cytotoxic TCR-T or CAR-T cells to a patient having a tumor expressing the tumor antigen, or administering CD8-positive cytotoxic CAR-T cells to a patient with an autoimmune disease.
- Treatment method 1b is a method for treating a tumor or an autoimmune disease by producing CD8-positive cytotoxic TCR-T, CAR-T or CAAR-T cells by the method for producing TCR/CAR/CAAR-expressing immune cells of aspect B, in which multipotent blood progenitor cells are induced to differentiate into immune cells and then an exogenous receptor gene is introduced, and administering the cells to a patient, and comprises the following steps 1b-1 to 1b-4.
- Step 1b-1 preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells.
- Step 1b-2 inducing differentiation of multipotent blood progenitor cells into T cells.
- Step 1b-3 is to prepare CD8-positive cytotoxic TCR-T, CAR-T or CAAR-T cells by TCR stimulation of T cells and then introducing a gene encoding an exogenous receptor that is a TCR or CAR that specifically recognizes a CAAR or a tumor antigen.
- Step 1b-4 which comprises administering CD8-positive cytotoxic TCR-T or CAR-T cells to a patient having a tumor expressing the tumor antigen, or administering CD8-positive cytotoxic CAR-T cells to a patient with an autoimmune disease.
- Treatment method 2a is a method for treating a tumor or an autoimmune disease by producing CAR-NK cells, CAAR-NK cells, CAR-macrophages or CAAR-macrophages by the method for producing TCR/CAR/CAAR-expressing immune cells of aspect A, in which an exogenous receptor gene is introduced into multipotent blood progenitor cells and then the cells are induced to differentiate into immune cells, and administering the cells to a patient, and comprises the following steps 2a-1 to 2a-4.
- Step 2a-1 preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells.
- Step 2a-2 is to prepare multipotent blood progenitor cells expressing a chimeric receptor, which is a CAAR or a CAR that specifically recognizes a tumor antigen, by introducing a gene encoding the chimeric receptor into the multipotent blood progenitor cells.
- Step 2a-4 administering CAR-NK cells or CAR-macrophages to a patient having a tumor expressing the above-mentioned tumor antigen, or administering CAR-NK cells or CAAR-macrophages to a patient with an autoimmune disease.
- CAR-NK cells, CAAR-NK cells, CAR-macrophages, and CAAR-macrophages have sufficient proliferation ability even before receptor stimulation, so these chimeric receptor-expressing immune cells can be administered to patients without receptor stimulation.
- the prepared chimeric receptor-expressing immune cells can be receptor-stimulated to further increase their proliferation ability before being administered to patients.
- Treatment method 2b is a method for treating a tumor or an autoimmune disease by producing CAR-NK cells, CAAR-NK cells, CAR-macrophages or CAAR-macrophages by the method for producing TCR/CAR/CAAR-expressing immune cells of aspect B, in which multipotent blood progenitor cells are induced to differentiate into immune cells and then an exogenous receptor gene is introduced, and administering the same to a patient, and comprises the following steps 2b-1 to 2b-4.
- Step 2b-1 preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells.
- Step 2b-2 inducing differentiation of multipotent blood progenitor cells into NK cells or macrophages.
- step 2b-3 of preparing CAR-NK cells, CAAR-NK cells, CAR-macrophages, or CAAR-macrophages by receptor stimulation of NK cells or macrophages and then introducing a gene encoding a chimeric receptor that is a CAR that specifically recognizes a CAAR or a tumor antigen.
- Step 2b-4 administering CAR-NK cells or CAR-macrophages to a patient having a tumor expressing the above-mentioned tumor antigen, or administering CAR-NK cells or CAAR-macrophages to a patient with an autoimmune disease.
- Treatment method 3 is a method of treating a tumor by administering a combination of CAR-macrophages and CAR-T cells to a patient, and includes the following steps 3-1 to 3-3.
- Step 3-1 preparing CAR-macrophages by the following (1) or (2): (1) preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells, introducing a gene encoding a CAR that specifically recognizes a tumor antigen into the multipotent blood progenitor cells to prepare multipotent blood progenitor cells expressing the CAR, and then inducing the differentiation of the CAR-expressing multipotent blood progenitor cells into macrophages; (2) A process of preparing artificial leukocyte stem cells or T/NK precursor cells from a cell population containing hematopoietic stem cells, inducing their differentiation into macrophages, stimulating the receptor, and then introducing a gene encoding the CAR.
- Step 3-2 of preparing CAR-T cells by the following (3) or (4): (3) preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells, introducing a gene encoding the CAR into the multipotent blood progenitor cells to prepare multipotent blood progenitor cells expressing the CAR, inducing the differentiation of the CAR-expressing multipotent blood progenitor cells into T cells, and then inducing the differentiation into CD8-positive cytotoxic TCR-T or CAR-T cells by TCR stimulation; (4) A process of preparing artificial leukocyte stem cells or T/NK precursor cells from a cell population containing hematopoietic stem cells, inducing differentiation into T cells, stimulating them with TCR, and then introducing a gene encoding the CAR.
- Step 3-3 is administering a combination of CAR-macrophages and CAR-T cells to a patient having a tumor expressing the tumor antigen.
- Treatment method 4 is a method of treating a tumor by administering a combination of CAR-macrophages and CAR-NK cells to a patient, and includes the following steps 4-1 to 4-3.
- Step 4-1 preparing CAR-macrophages by the following step (1) or (2): (1) preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells, introducing a gene encoding a CAR that specifically recognizes a tumor antigen into the multipotent blood progenitor cells to prepare multipotent blood progenitor cells expressing the CAR, and then inducing the differentiation of the CAR-expressing multipotent blood progenitor cells into macrophages; (2) A process of preparing artificial leukocyte stem cells or T/NK precursor cells from a cell population containing hematopoietic stem cells, inducing their differentiation into macrophages, stimulating the receptor, and then introducing a gene encoding the CAR.
- Step 4-2 preparing CAR-NK cells by the following step (5) or (6): (5) preparing multipotent blood progenitor cells from a cell population containing hematopoietic stem cells, and introducing a gene encoding the CAR into the multipotent blood progenitor cells to prepare multipotent blood progenitor cells expressing the CAR, and then inducing the differentiation of the CAR-expressing multipotent blood progenitor cells into NK cells; (6) A process of preparing artificial leukocyte stem cells or T/NK precursor cells from a cell population containing hematopoietic stem cells, inducing differentiation into NK cells, stimulating the receptor, and then introducing a gene encoding the CAR.
- Step 4-3 is administering a combination of CAR-macrophages and CAR-NK cells to a patient having a tumor expressing the tumor antigen.
- CAR-NK cells and CAR-macrophages have sufficient proliferation ability even before receptor stimulation, so receptor stimulation is not essential in steps 3-1(1), 4-1(1), and 4-2(5).
- the prepared CAR-NK cells and CAR-macrophages may be receptor-stimulated to further enhance their proliferation ability, and then administered to the patient.
- Steps 1a-1 to 1a-4 of therapeutic method 1a, steps 2a-1 to 2a-3 of therapeutic method 2a, steps 3-1(1) and 3-2(3) of therapeutic method 3, steps 4-1(1) and 4-2(5) of therapeutic method 4, and the optional steps of receptor stimulation of CAR-NK cells, CAAR-NK cells, CAR-macrophages, or CAAR-macrophages in therapeutic method 2a, therapeutic method 3, and therapeutic method 4 can be carried out as described in I-1. to I-3.
- Steps 1b-1 to 1b-3 of treatment method 1b, steps 2b-1 to 2b-3 of treatment method 2b, steps 3-1(2) and 3-2(4) of treatment method 3, and steps 4-1(2) and 4-2(6) of treatment method 4 can be carried out as described in I-1., I-4., and I-5.
- the multipotent blood progenitor cells or artificial white blood stem cells or T/NK progenitor cells may be prepared from umbilical cord blood (which is usually not derived from the patient himself), or a cell population containing hematopoietic stem cells may be obtained from bone marrow fluid or peripheral blood collected from the patient, and multipotent blood progenitor cells or artificial white blood stem cells or T/NK progenitor cells derived from the patient's own cells may be prepared.
- the immune cells expressing an exogenous receptor are prepared into an appropriate dosage form such as an intravenous infusion as described in III., and administered to a tumor patient or an autoimmune disease patient.
- the tumor patient to whom the immune cells are administered is a patient having a tumor expressing a tumor antigen recognized by an exogenous receptor (in this case, the receptor is an antigen-specific receptor) expressed in the immune cells.
- the autoimmune disease patient to whom the immune cells are administered is a patient having an autoimmune disease caused by an autoantigen adopted in the antigen-derived portion of CAAR expressed in the immune cells, or a pathogenic B cell that recognizes the autoantigen.
- the immune cells may be administered to the patient once, or two or more times at appropriate intervals.
- the CAR-macrophage and the CAR-T/CAR-NK cells may each be administered once, or two or more times at appropriate intervals.
- the meaning of the term "administered in combination" is as explained in III.
- the dose of each immune cell may vary depending on the type of cell to be administered, the type of tumor, the patient's body weight, etc., but it is sufficient to administer about 1 x 10 5 to 1 x 10 9 viable cells per administration.
- TCR-T/CAR-T/CAR-NK cells are administered after reducing lymphocytes in the patient's body through anticancer drug treatment or the like.
- a pretreatment may be performed to reduce lymphocytes in the patient's body prior to administration of immune cells expressing tumor antigen-specific TCR or CAR.
- the tumor to be treated is one that expresses a tumor antigen that is recognized by an exogenous receptor (in this case, an antigen-specific receptor).
- the autoimmune disease to be treated is one whose etiology is the autoantigen adopted in the antigen-derived portion of CAAR, or pathogenic B cells that recognize the autoantigen.
- Specific examples of tumors and autoimmune diseases are as given in I-2., along with specific examples of tumor antigens and autoantigens.
- RPMI-1640 Roswell Park Memorial Institute
- IMDM Isocove's Modified Dulbecco's Medium
- MEM ⁇ Minimum Essential Medium alpha
- Stemline II Stemline II
- All media were supplemented with 100 ⁇ g/mL penicillin and 100 U/mL streptomycin.
- RPMI-1640 and IMDM were supplemented with 10% fetal bovine serum (FBS; Gibco), and MEM ⁇ was supplemented with 20% FBS.
- FBS fetal bovine serum
- MEM ⁇ was supplemented with 20% FBS.
- RPMI-1640 supplemented with 1% MEM Non-Essential Amino Acid Solution (Gibco) and 1 mM Sodium Pyruvate (Gibco) was used as RPMI complete (RPMIcomp).
- Cytokines Recombinant human (rh) interleukin-2 (IL-2), IL-7, IL-15, FMS-related tyrosine kinase 3 ligand (Flt3-L), stem cell factor (SCF), thrombopoietin (TPO), and granulocyte-colony stimulating factor (G-CSF); recombinant mouse (rm) IL-3, IL-6, IL-7, IL-15, SCF, Flt3-L, TPO, and macrophage-stimulating factor (M-CSF) were purchased from R&D systems.
- the ID3-ERT2 retrovirus vector used was that previously reported (Non-Patent Document 3).
- This retrovirus vector was constructed by cloning the ID3-ERT2 gene, which is a fusion of the full-length human ID3 gene cDNA with the ligand-binding domain mutant of human estrogen receptor (ERT2) sequence, into the publicly known pCSRet retrovirus vector.
- positions 1 to 357 are human ID3 gene cDNA
- positions 370 to 1311 are the ERT2 ligand-binding domain mutant sequence.
- the plasmid (murine TCR OTI-2A.pMIG II) encoding the OTI-TCR gene (the gene for a T cell receptor that specifically responds to OVA antigen, Fig. 2, upper panel, SEQ ID NO: 17) was purchased from Addgene.
- positions 1 to 828 are the OTI TCR ⁇ chain sequence
- positions 829 to 882 are the T2A self-cleaving peptide sequence
- positions 883 to 1821 are the OTI TCR ⁇ chain sequence.
- the pMIGII-hCD19-m28z-CAR plasmid carrying the hCD19-m28z-CAR gene was constructed by fusing the 3xFlag gene, the human CD19-specific FMC63 antibody single chain variable region fragment gene, the cell membrane domain and intracellular signal domain of mouse CD28, and the mouse CD3 ⁇ intracellular signal domain gene downstream of the mouse IgG2a ⁇ signal peptide gene ( Figure 10B).
- positions 1 to 60 are the mouse IgG2a ⁇ signal peptide sequence
- positions 61 to 126 are the 3xFlag gene
- positions 127 to 870 are the human CD19-specific FMC63 antibody single chain variable region fragment gene
- positions 871 to 312 are the cell membrane domain and intracellular signal domain gene of mouse CD28
- positions 1183 to 1521 are the mouse CD3 ⁇ intracellular signal domain gene sequence.
- Retroviruses carrying these genes were produced by introducing the target plasmid and VSV-G plasmid into Plat E cells (Cell Biolabs Inc.) using FuGENE 6 Transfection Reagent (Roche).
- a CSII vector was used as the lentivirus vector.
- a plasmid encoding a gene of interest such as a CAR gene, a Gag/Pol plasmid, a Rev plasmid, and a VSV-G or GALV envelope plasmid were introduced into 293T cells using FuGENE 6 Transfection Reagent (Roche) to prepare a lentivirus expressing the gene of interest.
- the GALV envelope plasmid used was a commercially available phCMV-GALV-MTR containing the synthetic gene GALV-MTR (a gene encoding an envelope in which the membrane domain and cytoplasmic domain derived from Mouse Leukemia virus (MuLV) have been substituted for the corresponding regions of the GALV envelope, SEQ ID NO: 15).
- GALV-MTR a gene encoding an envelope in which the membrane domain and cytoplasmic domain derived from Mouse Leukemia virus (MuLV) have been substituted for the corresponding regions of the GALV envelope, SEQ ID NO: 15).
- the cells were harvested and the ID3-ERT2 gene was introduced by spin-infection using a retrovirus.
- human CD25 was used as a marker for gene introduction, and the ID3-ERT2 gene was linked to the human CD25 gene and introduced into the cells.
- Human CD25-positive ID3-ERT2 transfected cells were isolated using a cell sorter. The sorted iLS cells were cultured on OP9 cells in iLS cell medium (IMDM supplemented with 10 ng/mL rmIL-7, 10 ng/mL rmFlt3-L, 10 ng/mL rmSCF, and 40 nM 4-hydroxytamoxifen (4-OHT)). The iLS cells were passaged on fresh OP9 cells every 3-4 days for expansion. After about one month, stably proliferating iLS cells were confirmed by FCM analysis and used for subsequent experiments ( Figure 1).
- A-2-2 Transfection of cancer-specific receptors into iLS cells into iLS cells
- the OTI-TCR gene or the hCD19-m28z-CAR gene was introduced into iLS cells by spin-infection using a retrovirus. After gene introduction, iLS cells positive for the marker protein GFP were isolated using a cell sorter.
- the isolated OTI-TCR gene-transfected iLS (OTI TCR-iLS) cells and hCD19-m28z-CAR gene-transfected iLS (CD19-CAR iLS) cells were cultured under iLS cell culture conditions and maintained and expanded ( Figures 2 and 10).
- A-2-3 T cell induction from cancer-specific receptor gene-transduced iLS cells
- OTI TCR-iLS cells or CD19-CAR iLS cells were seeded on OP9/Delta-like 1 (OP9/DLL1) cells and cultured in MEM ⁇ supplemented with 5 ng/mL rmIL-7, 5 ng/mL rmFlt3-L, and 40 nM 4-OHT.
- Half of the medium was replaced with the above medium excluding 4-OHT every 3-4 days, and after one week, the iLS cells were seeded on new OP9/DLL1 cells.
- the cells were cultured in MEM ⁇ containing 1 ng/mL rmIL-7 and 1 ng/mL rmFlt3-L. Three weeks after the start of induction, the cells were harvested, and CD4/CD8 double positive (DP) cells were isolated using CD8a (Ly-2) MicroBeads (Miltenyi Biotech) ( Figures 3, 4, 6).
- spleen cells were harvested from C57BL/6 mice, treated with 10 ⁇ g/mL mitomycin C (MMC) for 2.5 h, and used as antigen-presenting cells.
- MMC mitomycin C
- the DP cells derived from OTI TCR-iLS cells and the MMC-treated antigen-presenting cells were mixed at a 2:1 ratio and co-cultured in RPMIcomp medium containing 5 ng/mL rmIL-7, 5 ng/mL rmIL-15, 50 IU/mL rhIL-2, and 10 ⁇ g/mL OVA peptide (OVA 257-264 ), resulting in the generation of CD8 T cells ( Figure 5).
- DP cells generated from CD19-CAR iLS cells were TCR stimulated by culturing them on plates coated with anti-CD3 and anti-CD28 antibodies in RPMIcomp medium supplemented with 5 ng/mL rmIL-7, 5 ng/mL rmIL-15, and 50 IU/mL rhIL-2.
- RPMIcomp medium supplemented with 5 ng/mL rmIL-7, 5 ng/mL rmIL-15, and 50 IU/mL rhIL-2 without TCR stimulation.
- OVA antigen-presenting cells were obtained by culturing spleen cells collected from C57BL/6 mice with 1 ⁇ g/mL OVA 257-264 for 1 hour.
- CD8+ T cells derived from OTI TCR-iLS cells were mixed with 10 times the amount of OVA antigen-presenting cells or treated with 10 ng/mL PMA and 1 ⁇ g/mL ionomycin, and cultured in RPMIcomp medium supplemented with 1/1000 amount of PE-Cy7-conjugated CD107a antibody and 1xProtein transport inhibitor (eBioscience).
- A-2-5 Cytotoxic activity of CD8+ T cells derived from OTI TCR-iLS cells.
- B16 cells stably expressing OVA antigen (B16-OVA) or B16 cells expressing only the selection marker neomycin (B16-Neo) treated with 500 ng/mL IFN ⁇ overnight were stained with Cell Tracer Far-Red (Invitrogen). Then, they were mixed with CD8+ T cells derived from OTI TCR-iLS cells or CD8T cells from the spleen of OTI Tg mice (transgenic mice expressing the OTI-TCR gene) at different ratios and co-cultured for 18 hours in RPMIcomp medium supplemented with 50 IU/mL rhIL-2.
- A-2-6 In vivo antitumor activity of CD8 positive T cells derived from OTI TCR-iLS cells 1x10 5 B16-OVA cells were subcutaneously transplanted into C57BL/6 mice to generate B16-OVA tumor-bearing mice. Five days after transplantation, the tumor-bearing mice were irradiated with 4 Gy X-rays, and then 3x10 6 OTI TCR T-iLS cells were administered via the tail vein. 50,000 IU rhIL-2 was administered intraperitoneally once a day for three days from the day of T cell transplantation. The tumor diameter was measured over time to evaluate the antitumor activity of TCR-T cells. The tumor volume was calculated as (short side) 2 x (long side) x 0.5. As a result, iLS-derived OTI TCR-T cells showed the same antitumor activity as T cells derived from OTI Tg mice ( Figure 9).
- CD19-CAR iLS cells were seeded on OP9 cells and cultured for 10 days in RPMIcomp medium supplemented with 10 ng/mL rmIL-15 and 100 IU/mL rhIL-2. As a result, a high percentage of CAR-NK cells were generated (Figure 10).
- CD19-CAR iLS cells were seeded on OP9 cells and cultured in IMDM supplemented with 10 ng/mL rmSCF, 5 ng/mL rmM-CSF, 5 ng/mL rmIL-3, and 5 ng/mL rmIL-6. Half of the medium was replaced after 4 days. After one week of culture from the start of induction, FCM analysis confirmed the generation of CD11b-positive F4/80-positive MHC class II (IA)-positive macrophages ( Figure 12). Therefore, it was revealed that CAR iLS cells have the ability to generate CAR-macrophages.
- IA MHC class II
- hCB-CD34 positive cells were obtained from the RIKEN BioResource Research Center.
- hCB-CD34 positive cells were cultured and expanded for one week in Stemline II medium supplemented with 100 ng/mL rhSCF, 100 ng/mL rhTPO, and 100 ng/mL rhG-CSF.
- hCB-HSPCs expanded in Stemline II medium were seeded on OP9/DLL1 cells and induced into NK cells by culturing with 20 ng/mL rhIL-7, 10 ng/mL rhFlt3-L, 20 ng/mL rhSCF, and 10 ng/mL rhIL-15.
- pT/NK cells generated 17 times more NK cells than hCB-HSPCs ( Figure 13, lower right).
- NK cells were mixed with the target cell leukemia cell line K562 cell line (K562 cells) or treated with 10 ng/mL PMA and 1 ⁇ g/mL ionomycin, and cultured in MEM ⁇ medium containing 1/500 amount of APC-bound CD107a antibody and 1x Protein transport inhibitor. After 4 hours, intracellular staining was performed and FCM analysis of cytokines was performed, revealing that they were activated by the target cells ( Figure 14).
- CAR-NK cells were produced by transferring a CAR gene into pT/NK cell-derived NK cells.
- the CAR genes used were the anti-CD19 CAR gene (SEQ ID NOs: 11 and 12) that specifically recognizes human CD19 and was constructed using a human protein in the intracellular domain, and the anti-GD2 CAR gene (SEQ ID NOs: 13 and 14) that encodes a CAR that specifically recognizes GD2, a neuroblastoma antigen.
- positions 1-63 (1-21 AA of SEQ ID NO:12) are the CD8 ⁇ signal peptide sequence
- positions 64-129 (22-43 AA) are the 3xFlag gene
- positions 130-864 are the anti-CD19 scFv (antibody clone FMC63) gene
- positions 874-1014 (292-338 AA) are the human CD8 ⁇ hinge region gene
- positions 1024-1119 are the human CD28 transmembrane domain gene
- positions 1120-1245 (374-415 AA) are the human 4-1BB intracellular signal domain gene
- positions 1252-1593 (418-531 AA) are the human CD3 ⁇ intracellular signal domain gene.
- positions 130-867 are the anti-GD2 scFv (antibody Clone 14g2a) gene, and the upstream and downstream sequences are identical to SEQ ID NO: 11 (positions 1-63 (1-21 AA) are the CD8 ⁇ signal peptide sequence, positions 64-129 (22-43 AA) are the 3xFlag sequence, positions 877-1017 (293-339 AA) are the human CD8 ⁇ hinge region, positions 1027-1122 (343-374 AA) are the human CD28 transmembrane domain, positions 1123-1248 (375-416 AA) are the human 4-1BB intracellular signal domain, and positions 1255-1596 (419-532 AA) are the human CD3 ⁇ intracellular signal domain).
- K562 (K562/memIL-21/41BBL) cells stably expressing membrane-bound IL-21 (memIL-21) and 4-1BB ligand (41BBL) were treated with 10 ⁇ g/mL mitomycin C for 2.5 h.
- NK cells were expanded by mixing mitomycin C-treated K562/memIL-21/41BBL cells with pT/NK cell-derived NK cells at a 2:1 ratio and culturing in MEM ⁇ medium supplemented with 200 IU/mL rhIL-2.
- NK cells were cultured in MEM ⁇ medium containing 10 ng/mL rhIL-15, 10 ng/mL rhIL-21, and 100 IU/mL rhIL-2 for 2 days and transfected with anti-CD19 or anti-GD2 CAR genes using lentivirus by spin-infection.
- CAR-NK cells positive for the marker protein Venus were isolated using a cell sorter and then further expanded by co-culture with K562/memIL-21/41BBL cells. After expansion, FCM analysis of Venus expression was performed to confirm that all cells maintained expression of the introduced gene (Figure 16A).
- A-2-15 Cytotoxic activity of pT/NK cell-derived anti-CD19 CAR-NK cells
- NALM6 cells which are a B cell leukemia strain and express the CD19 antigen
- pT/NK cell-derived anti-CD19 CAR-NK cells were mixed with NALM6 cells at a 1:1 ratio and co-cultured for 4 hours.
- dead cells were stained with Live/Dead Near-IR (Invitrogen) and the proportion of dead cells was measured using FCM analysis, and the CAR-NK cells showed antigen-specific cytotoxic activity (Figure 16B).
- a lentivirus encoding the CAR gene which was produced using the GALV envelope (SEQ ID NO: 16), was introduced into the generated pT/NK cells.
- the lentivirus was seeded on a plate coated with Retronectin, centrifuged at 2000xg for 1.5 hours, and the lentivirus was allowed to bind to Retronectin, after which pT/NK cells were seeded. After centrifugation at 800xg for 10 minutes, the cells were cultured in an incubator.
- the cells into which the CAR gene had been introduced were sorted using a cell sorter to obtain CAR gene-introduced pT/NK cells (CAR-pT/NK cells) ( Figure 18A).
- the obtained CAR-pT/NK cells were cultured under NK cell-inducing conditions to obtain pT/NK cell-derived NK cells stably expressing the CAR gene ( Figure 18B).
- Figure 19 shows the results of measuring the number of pT/NK cells after culturing mouse HSPCs (Lineage-Sca1-ckit+: LSK) on OP9/DLL1 feeder cells for two weeks in medium containing SCF, IL-7, and Flt3-L at concentrations of 10 ng/ml or 30 ng/ml each. Even at 10 ng/ml, a large number of pT/NK cells (approximately 10,000 cells) were generated from a single HSPC. However, when the concentration of each cytokine was increased to 30 ng/ml, the number of pT/NK cells generated from a single HSPC was further expanded to approximately 60,000 cells.
- human pT/NK cells were not expanded when high concentrations ( ⁇ 25ng/ml) of cytokines were added, as shown in Figure 20, and it was revealed that human pT/NK cells could be expanded most efficiently when rhIL-7, rhFlt3-L, and rhSCF were each added at 5ng/ml. Based on these results, in the above A-2-10, each cytokine was used at 5ng/ml.
- NK cells generated using pT/NK cells was evaluated.
- the culture protocol is shown in Figure 21A.
- CD34 positive cells were cultured for one week in Stemline II medium supplemented with 100ng/ml rhTPO, 100ng/ml rhSCF, and 100ng/ml rhG-CSF.
- the expanded HSPCs were cultured on OP9/DLL1 cells in MEM ⁇ medium containing 5ng/ml rhIL-7, 5ng/ml rhFlt3-L, and 5ng/ml rhSCF to generate and expand pT/NK cells.
- pT/NK cells were induced to differentiate into NK cells by culturing in MEM ⁇ medium containing 10ng/ml rhIL-15, 10ng/ml rhFlt3-L, 20ng/ml rhIL-7, and 20ng/ml rhSCF in the absence of Notch signal.
- MEM ⁇ medium containing 10ng/ml rhIL-15, 10ng/ml rhFlt3-L, 20ng/ml rhIL-7, and 20ng/ml rhSCF in the absence of Notch signal.
- NK cells were directly induced to differentiate using a previously reported culture method (Li et al., Cell Stem Cell, Vol.
- FIG. 21B shows the proliferation rate of cells from CB-CD34 positive cells.
- Figure 21C shows the results of FCM analysis after NK cell generation.
- FIG. 21D shows the number of NK cells produced when NK cells were directly induced from HSPCs (conventional method) and when the pT/NK cell expansion method was used.
- NK cells produced from pT/NK cells were produced than the conventional method.
- the amount of NK cells produced from pT/NK cells was 17 times that of the conventional method. Therefore, when comparing the present method, in which culture is performed in the absence of a Notch signal when inducing differentiation of NK cells, with the method described in A-2-11, the amount of NK cells produced by the present method is about 12-30 times that of the method described in A-2-11, and the amount of NK cells produced by the present method can be further significantly improved.
- NK cells derived from human pT/NK cells The proliferative capacity of NK cells derived from pT/NK cells was evaluated.
- NK cells collected from CB (human umbilical cord blood) or PB (human peripheral blood) CB-NK and PB-NK, respectively
- Figure 22A shows the cell proliferation rate after 2 weeks of culture in MEM ⁇ medium supplemented with 10 ng/ml rhIL-15.
- Figure 22B shows the cell count when NK cells were expanded in MEM ⁇ medium containing 200 IU/ml rhIL-2 after mixing with MMC (mitomycin)-treated aAPC (artificial antigen presenting cells, cells expressing a ligand that stimulates NK cells) at an E:T ratio of 1:2.
- MMC mitomycin
- aAPC artificial antigen presenting cells, cells expressing a ligand that stimulates NK cells
- NK cells derived from human pT/NK cells were evaluated by FCM analysis.
- the expression levels of NKp44, NKp46, and NKG2D in pT/NK-derived NK cells were comparable to those of CB-NK cells and PB-NK cells.
- the expression levels of CD16 and KIR2DL2/L3 were lower than those of PB-NK cells, and the expression levels of NKG2A were lower than those of CB-NK cells.
- NK cells and K562 cells were mixed at various E:T ratios and then co-cultured for 4 hours. After culture, the percentage of dead K562 cells was evaluated by FCM analysis (Fig. 24A). To evaluate the expression level of effector molecules of activated NK cells, NK cells and K562 cells were mixed at an E:T ratio of 1:2 and cultured in MEM ⁇ medium containing 1/500 of APC-bound CD107a antibody and 1x Protein transport inhibitor.
- cytokines was analyzed by FCM (Fig. 24B).
- the pT/NK-derived NK cells showed high cytotoxic activity comparable to that of CB-NK cells and PB-NK cells, and the expression levels of effector molecules upon stimulation with K562 cells were also comparable to those of CB-NK cells and PB-NK cells (Fig. 24C).
- the cells were expanded by about 200-650 times by co-culture for 2 weeks, confirming that the proliferation ability of NK cells was not lost by cryopreservation (Figure 25B).
- the pT/NK cell-derived NK cells were co-cultured in a medium supplemented with aAPC and 200 IU/ml rhIL-2, and then the cytotoxic activity against K562 cells was evaluated.
- the percentage of dead K562 cells was measured by FCM analysis, and the results showed that the NK cells derived from frozen pT/NK cells maintained the same high cytotoxic activity as before freezing (Figure 25C).
- NK cell production ability of human pT/NK cells expanded by TPO or M-CSF The differentiation ability of pT/NK cells expanded by adding TPO or M-CSF into NK cells was evaluated. That is, hCB-HSPCs were cultured on OP9/DLL1 cells in a medium containing 5ng/ml rhIL-7, 5ng/ml rhFlt3-L, 5ng/ml rhSCF, and 25ng/ml TPO or M-CSF for 4 weeks to expand pT/NK cells.
- pT/NK cells were induced to differentiate into NK cells by culturing them in MEM ⁇ medium containing 10ng/ml rhIL-15, 10ng/ml rhFlt3-L, 20ng/ml rhIL-7, and 20ng/ml rhSCF.
- MEM ⁇ medium containing 10ng/ml rhIL-15, 10ng/ml rhFlt3-L, 20ng/ml rhIL-7, and 20ng/ml rhSCF.
- human bone marrow-derived CD34+ cells were cultured for 1 week in Stemline II medium containing 100ng/ml rhTPO, 100ng/ml rhSCF, and 100ng/ml rhG-CSF, and then cultured on OP9/DLL1 cells for 8 weeks in MEM ⁇ medium containing 5ng/ml rhIL-7, 5ng/ml rhFlt3-L, 5ng/ml rhSCF, and 25ng/ml TPO to generate and expand pT/NK cells.
- NK cells derived from pT/NK cells induced from human HSPCs The expression levels of NK cell-associated receptors on NK cells derived from pT/NK cells induced from human bone marrow HSPCs (hBM-pT/NK-derived NK cells) were evaluated by FCM analysis. As a result, similar to hCB blood-derived NK cells, expression of NKp44, NKp46, and NKG2D was observed, but expression of CD16 and KIR (KIR2DL2/L3) was low, suggesting that these are NK cells at an early stage of maturation (Figure 30A).
- Figure 30B shows the results of comparing the expression of activating receptors, inhibitory receptors, and exhaustion markers in NK cells derived from human T/NK precursor cells (pT/NK-NK cells), human CB-NK cells, and human PB-NK cells induced from human umbilical cord blood HSPCs.
- CB-NK cells are known to be immature NK cells with a low degree of maturity, but human pT/NK-NK cells are characterized as being even more immature than CB-NK cells.
- human pT/NK-NK cells also had lower expression of TIGIT, an exhaustion marker, than CB-NK cells, and were characterized as being less exhausted.
- Figure 30C shows RNA-seq data comparing gene expression in human pT/NK-NK cells, human CB-NK cells, and human PB-NK cells induced from human umbilical cord blood HSPCs.
- Human pT/NK-NK cells (NK.pTNK_1-3) showed higher expression of CCR3, CCR6, CCR7, CCR8, and CCR9 compared to human CB-NK cells (NK.CB_1-3) and human PB-NK cells (NK.PB_1-3).
- NK cells differentiated from bone marrow HSPCs The cytotoxic activity of NK cells derived from hBM-pT/NK cells against K562 cells was evaluated. NK cells and K562 cells were mixed at various E:T ratios and co-cultured for 4 hours. FCM analysis of the percentage of dead K562 cells after culture showed that NK cells derived from hBM-pT/NK cells showed high anti-cancer activity against K562 cells ( Figure 31).
- pT/NK cells include three fractions: ProT1 (CD7 + CD5 - CD1a - ) cells, ProT2 (CD7 + CD5 + CD1a - ) cells, and PreT (CD7 + CD5 + CD1a + ) cells.
- CD122 was not expressed in CD34 + CD7 - cells, which are hematopoietic precursor cells before receiving the Notch signal, and was highly expressed in ProT1 (CD7 + CD5 - CD1a - ) cells and ProT2 (CD7 + CD5 + CD1a - ) cells, and its expression was reduced in PreT (CD7 + CD5 + CD1a + ) cells.
- CD122 is used as a marker for NK precursor cells in mice (Non-Patent Document 4), but has not been reported in humans. Thus, CD122 was considered to be a novel marker molecule for human T/NK precursor cells. To evaluate the proliferation ability of these CD122-positive cells, a CFSE assay was performed (Fig. 32B).
- CD122-positive cells were isolated using a cell sorter and cultured on OP9/DLL1 cells in the presence of 5 ng/ml rhIL-7, 5 ng/ml rhFlt3-L, and 5 ng/ml rhSCF for one week, and the fluorescence intensity of CFSE was analyzed by FCM. As a result, it was shown that CD122-positive cells have high proliferation ability. Next, the differentiation ability of CD122-positive cells into T cells and NK cells was evaluated (Fig. 32C).
- CD122-positive cells After culturing hCB-derived HSPCs on OP9/DLL1 cells for two weeks, lineage marker-negative CD122-positive cells were isolated using a cell sorter and cultured under T cell and NK cell induction conditions. CD122-positive cells generated both CD4/CD8 double positive (DP) cells and CD56-positive NK cells, suggesting that they were pT/NK cells.
- CAR retroviral vector The anti-CD19 CAR gene or anti-HER2 CAR gene was loaded into the pMYs-IG retroviral vector to produce the pMYs-CD19 CAR-BBz-IG (middle row of Figure 33) and pMYs-HER2 CAR-BBz-IG (lower row of Figure 33) vectors.
- CAR-NK cells generated from pT/NK cell-derived NK cells CAR gene was introduced into pT/NK cell-derived NK cells by spin-infection using retrovirus.
- CAR-NK cells positive for GFP, a marker protein were isolated by cell sorter and further expanded by co-culture with aAPC. After culture, GFP expression was analyzed by FCM to confirm stable expression of the introduced gene (Fig. 34A). Next, the antigen-specific cytotoxic activity of anti-CD19 CAR-NK cells or anti-HER2 CAR-NK cells was evaluated.
- Anti-CD19 CAR-NK cells derived from pT/NK cells were mixed with CD19 antigen-positive B-cell leukemia cell line NALM6 (NALM6 cells) and anti-HER2 CAR-NK cells were mixed with HER2 antigen-positive breast cancer cell line MDA-MB-453 (MDA-MB-453 cells) at various E:T ratios, and co-cultured for 4 hours. The percentage of dead target cells was measured by FCM analysis. As a result, both anti-CD19 CAR-NK cells and anti-HER2 CAR-NK cells showed higher cytotoxic activity against target cells compared to mock NK cells (Figure 34B).
- C-3 Introduction of CAR gene into pT/NK cells
- Anti-CD19 CAR gene or anti-HER2 CAR gene was introduced into pT/NK cells, and cells expressing GFP, a marker protein, were isolated using a cell sorter, and then cultured on OP9/DLL1 cells in the presence of 5ng/ml rhIL-7, 5ng/ml rhFlt3-L, and 5ng/ml rhSCF for 2 weeks to expand.
- FCM analysis of GFP expression in pT/NK cells after culture showed that pT/NK cells stably expressed the introduced gene (Figure 35).
- FIG. 36A shows a scheme for producing CAR-NK cells from CAR-pT/NK cells.
- CAR-pT/NK cells were cultured on OP9/DLL1 cells in the presence of 5ng/ml rhIL-7, 5ng/ml rhFlt3-L, and 5ng/ml rhSCF for expansion, and then induced into NK cells by culturing in MEM ⁇ medium containing 10ng/ml rhIL-15, 10ng/ml rhFlt3-L, 20ng/ml IL-7, and 20ng/ml rhSCF.
- the obtained CAR-NK cells were expanded by culturing in a medium containing aAPC and 200 IU/ml rhIL-2 for 2 weeks.
- Figure 36B shows the results of FCM analysis of CAR-NK cells derived from CAR-pT/NK cells on day 42 of culture, confirming that NK cells stably expressing the introduced gene were produced. It was also revealed that approximately 1 x 104 CAR-NK cells were produced per CAR-pT/NK cell (Figure 36C).
- Cytotoxic activity of CAR-pT/NK cell-derived CAR-NK cells The cytotoxic activity of CAR-pT/NK cell-derived CAR-NK cells against target cells was evaluated. Anti-CD19 CAR-NK cells and NALM6 cells, or anti-HER2 CAR-NK cells and MDA-MB-453 cells were co-cultured for 4 hours, and then FCM analysis was performed. The results showed that both had antigen-specific cytotoxic activity (Figure 37).
- C-6 Expression of cell surface markers of CAR-pT/NK cell-derived CAR-NK cells
- the expression levels of representative NK cell-associated receptors in pT/NK-derived anti-HER2 CAR-NK cells, CB-derived anti-HER2 CAR-NK cells, and PB-derived anti-HER2 CAR-NK cells were analyzed by FCM. The results are shown in Figure 38.
- pT/NK cell-derived anti-HER2 CAR-NK cells showed a more mature NK cell phenotype than CB-derived anti-HER2 CAR-NK cells and PB-derived anti-HER2 CAR-NK cells.
- pT/NK cell-derived anti-HER2 CAR-NK cells showed lower expression levels of TIGIT than CB-derived anti-HER2 CAR-NK cells and PB-derived anti-HER2 CAR-NK cells.
- C-7 Cytotoxic activity of CAR-pT/NK cell-derived CAR-NK cells After co-culture of pT/NK, CB-NK, and PB-NK-derived anti-HER2 CAR-NK cells with MDA-MB-453 for 4 hours, the percentage of dead MDA-MB-453 cells was measured by FCM analysis. As a result, pT/NK cell-derived anti-HER2 CAR-NK cells showed superior anti-cancer activity to CB-derived anti-HER2 CAR-NK cells and PB-derived anti-HER2 CAR-NK cells ( Figure 39).
- C-8 In vivo antitumor activity of CAR-pT/NK cell-derived CAR-NK cells The in vivo antitumor activity of pT/NK cell-derived anti-HER2 CAR-NK cells was evaluated.
- 1 x 106 luciferase-stably expressing MDA-MB-453 cells were subcutaneously implanted into NOD.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020267006528A KR20260047608A (ko) | 2023-08-04 | 2024-08-02 | 면역 세포의 제조 방법 |
| JP2025539483A JPWO2025033358A1 (cg-RX-API-DMAC7.html) | 2023-08-04 | 2024-08-02 | |
| EP24851783.1A EP4756030A1 (en) | 2023-08-04 | 2024-08-02 | Method for producing immune cells |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023-127747 | 2023-08-04 | ||
| JP2023127747 | 2023-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2025033358A1 true WO2025033358A1 (ja) | 2025-02-13 |
Family
ID=94534808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2024/027781 Ceased WO2025033358A1 (ja) | 2023-08-04 | 2024-08-02 | 免疫細胞の製造方法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4756030A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2025033358A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20260047608A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2025033358A1 (cg-RX-API-DMAC7.html) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009113595A1 (ja) | 2008-03-11 | 2009-09-17 | 独立行政法人理化学研究所 | 造血幹/前駆細胞の特性を有する細胞の製造方法 |
| WO2016007006A2 (en) | 2014-07-10 | 2016-01-14 | Bluecup B.V. | Coffee cup and method and device for making a coffee cup |
| WO2016010154A1 (ja) * | 2014-07-18 | 2016-01-21 | 宏 河本 | 抗原特異的t細胞受容体遺伝子を有する多能性幹細胞の製造方法 |
| JP2016539659A (ja) * | 2013-10-24 | 2016-12-22 | オスペダーレ サン ラファエレ エス.アール.エル | 方法 |
| WO2018168829A1 (ja) * | 2017-03-14 | 2018-09-20 | 国立大学法人京都大学 | 多能性幹細胞からヘルパーt細胞を製造する方法 |
| WO2020022512A1 (ja) * | 2018-07-26 | 2020-01-30 | 国立大学法人京都大学 | 外来抗原レセプター遺伝子導入細胞の製造方法 |
| JP2020517237A (ja) * | 2017-04-18 | 2020-06-18 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | 抗原特異的免疫エフェクター細胞 |
| JP2021518130A (ja) * | 2018-03-23 | 2021-08-02 | サントル ナショナル デ ラ ルシェルシュ シアンティフィック | 多能性幹細胞からt細胞を入手するための新規な方法およびその使用 |
| JP2021525066A (ja) * | 2018-05-30 | 2021-09-24 | グリコステム セラピューティクス ベスローテン フェンノートシャップ | Car nk細胞 |
| WO2022196719A1 (ja) | 2021-03-17 | 2022-09-22 | 第一三共株式会社 | 抗アセチルコリン受容体自己抗体に対するキメラ受容体をコードする遺伝子 |
| WO2023060163A2 (en) * | 2021-10-06 | 2023-04-13 | Board Of Regents, The University Of Texas System | Shp1 modified dendritic cells and extracellular vesicles derived therefrom and associated methods |
-
2024
- 2024-08-02 JP JP2025539483A patent/JPWO2025033358A1/ja active Pending
- 2024-08-02 WO PCT/JP2024/027781 patent/WO2025033358A1/ja not_active Ceased
- 2024-08-02 KR KR1020267006528A patent/KR20260047608A/ko active Pending
- 2024-08-02 EP EP24851783.1A patent/EP4756030A1/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009113595A1 (ja) | 2008-03-11 | 2009-09-17 | 独立行政法人理化学研究所 | 造血幹/前駆細胞の特性を有する細胞の製造方法 |
| JP2016539659A (ja) * | 2013-10-24 | 2016-12-22 | オスペダーレ サン ラファエレ エス.アール.エル | 方法 |
| WO2016007006A2 (en) | 2014-07-10 | 2016-01-14 | Bluecup B.V. | Coffee cup and method and device for making a coffee cup |
| WO2016010154A1 (ja) * | 2014-07-18 | 2016-01-21 | 宏 河本 | 抗原特異的t細胞受容体遺伝子を有する多能性幹細胞の製造方法 |
| WO2018168829A1 (ja) * | 2017-03-14 | 2018-09-20 | 国立大学法人京都大学 | 多能性幹細胞からヘルパーt細胞を製造する方法 |
| JP2020517237A (ja) * | 2017-04-18 | 2020-06-18 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | 抗原特異的免疫エフェクター細胞 |
| JP2021518130A (ja) * | 2018-03-23 | 2021-08-02 | サントル ナショナル デ ラ ルシェルシュ シアンティフィック | 多能性幹細胞からt細胞を入手するための新規な方法およびその使用 |
| JP2021525066A (ja) * | 2018-05-30 | 2021-09-24 | グリコステム セラピューティクス ベスローテン フェンノートシャップ | Car nk細胞 |
| WO2020022512A1 (ja) * | 2018-07-26 | 2020-01-30 | 国立大学法人京都大学 | 外来抗原レセプター遺伝子導入細胞の製造方法 |
| WO2022196719A1 (ja) | 2021-03-17 | 2022-09-22 | 第一三共株式会社 | 抗アセチルコリン受容体自己抗体に対するキメラ受容体をコードする遺伝子 |
| WO2023060163A2 (en) * | 2021-10-06 | 2023-04-13 | Board Of Regents, The University Of Texas System | Shp1 modified dendritic cells and extracellular vesicles derived therefrom and associated methods |
Non-Patent Citations (16)
| Title |
|---|
| "GenBank", Database accession no. AF055060.1 |
| ADAM C. WILKINSON ET AL., NATURE, vol. 571, 2019, pages 117 - 121 |
| CAESER ET AL., NAT COMMUN, vol. 10, no. 1, 4 October 2019 (2019-10-04), pages 4543 |
| ELLEBRECHT ET AL., SCIENCE, vol. 353, 8 July 2016 (2016-07-08), pages 179 - 184 |
| GUOZHU XIE ET AL., EBIOMEDICINE, vol. 59, 2020, pages 102975 |
| IKAWA ET AL., J EXP MED., vol. 190, 6 December 1999 (1999-12-06), pages 1617 - 1625 |
| IKAWA ET AL., PNAS, vol. 98, 24 April 2001 (2001-04-24), pages 5164 - 5169 |
| IKAWA ET AL., SCIENCE, vol. 329, 2 July 2010 (2010-07-02), pages 93 - 96 |
| IKAWA ET AL., STEM CELL REP, vol. 5, 10 November 2015 (2015-11-10), pages 716 - 727 |
| IKAWA TOMOKATSU, MASUDA KYOKO, HUIJSKENS MIRELLE J.A.J., SATOH RUMI, KAKUGAWA KIYOKAZU, AGATA YASUTOSHI, MIYAI TOMOHIRO, GERMERAAD: "Induced Developmental Arrest of Early Hematopoietic Progenitors Leads to the Generation of Leukocyte Stem Cells", STEM CELL REPORTS, CELL PRESS, UNITED STATES, vol. 5, no. 5, 1 November 2015 (2015-11-01), United States , pages 716 - 727, XP093273282, ISSN: 2213-6711, DOI: 10.1016/j.stemcr.2015.09.012 * |
| J. BIOL. CHEM., vol. 282, 2007, pages 27383 - 27391 |
| LI ET AL., CELL STEM CELL, vol. 23, 2 August 2018 (2018-08-02), pages 181 - 192 |
| MENSALI ET AL., EBIOMED, vol. 40, 2019, pages 106 - 117 |
| NORTON, J.D ET AL., TRENDS CELL BIOL, vol. 8, 1998, pages 58 - 65 |
| PAASCH DANIELA, MEYER JOHANN, STAMOPOULOU ANDRIANA, LENZ DANIELA, KUEHLE JOHANNES, KLOOS DOREEN, BUCHEGGER THERESA, HOLZINGER ASTR: "Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy", CELLS, MDPI AG, vol. 11, no. 6, 15 March 2022 (2022-03-15), pages 994, XP093242488, ISSN: 2073-4409, DOI: 10.3390/cells11060994 * |
| SAYEGH, C.E ET AL., NAT. IMMUNOL, vol. 4, 2003, pages 586 - 593 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4756030A1 (en) | 2026-06-10 |
| JPWO2025033358A1 (cg-RX-API-DMAC7.html) | 2025-02-13 |
| KR20260047608A (ko) | 2026-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11065278B2 (en) | Method and compositions for cellular immunotherapy | |
| ES2912383T3 (es) | Células efectoras inmunitarias específicas de antígeno | |
| JP2021121198A (ja) | 免疫機能制御因子を発現する免疫担当細胞 | |
| JP2023516632A (ja) | 多能性幹細胞からナチュラルキラー細胞を産生するための方法 | |
| JP2022542321A (ja) | 免疫療法のためのnk細胞組成物および調製物ならびにそれらの製造のための方法 | |
| JP2018531022A (ja) | 改変ヒト初代血液樹状細胞株を生成するための方法 | |
| JP2018531022A6 (ja) | 改変ヒト初代血液樹状細胞株を生成するための方法 | |
| Payne et al. | Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy | |
| JP7179986B2 (ja) | 形質転換されたt細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法 | |
| JP2023504075A (ja) | Car-nk細胞を得る方法 | |
| CN118871572A (zh) | 使用多种t细胞受体对干细胞t细胞进行工程化 | |
| KR20260047608A (ko) | 면역 세포의 제조 방법 | |
| JP2024517966A (ja) | 同種異系car t細胞療法のために幹細胞を操作すること | |
| JP2024517968A (ja) | 幹細胞からの操作されたt細胞の産生 | |
| US20260053856A1 (en) | Immunocompetent cell and expression vector expressing regulatory factors of immune function / a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19 | |
| WO2025220666A1 (en) | Cytotoxic Lymphocytes Expressing Variable Region-Deleted T Cell Receptors | |
| WO2023249071A1 (ja) | T細胞受容体 | |
| NZ714574A (en) | Method and compositions for cellular immunotherapy | |
| NZ714574B2 (en) | Method and compositions for cellular immunotherapy | |
| NZ726162B2 (en) | Method and compositions for cellular immunotherapy | |
| HK1193431B (en) | Method and compositions for cellular immunotherapy | |
| HK1193431A (en) | Method and compositions for cellular immunotherapy | |
| HK1130509A1 (en) | Method for production of t cell population |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24851783 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2025539483 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2025539483 Country of ref document: JP |
|
| ENP | Entry into the national phase |
Ref document number: 1020267006528 Country of ref document: KR Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A15-NAP-PA0105 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020267006528 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024851783 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020267006528 Country of ref document: KR |